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Abstract  
 
Background and objectives: 
 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by 
the relentless loss of upper motor neurones (UMN) and lower motor neurones (LMN), 
leading to progressive weakness. The cause of ALS is unknown and there are currently no 
curative treatments. The median survival is 18 months from diagnosis, however, the rate of 
disease progression and survival vary significantly among individual ALS patients. 
 
In the absence of a cure for ALS, discovery of factors that modify disease 
progression is critical. An understanding of processes that influence the course of ALS 
could shed light on disease mechanisms and identify therapeutic targets that could be 
manipulated in order to prolong survival.   
 
Systemic energy metabolism is emerging as an important modifying factor in ALS. 
Of clinical significance, adiposity [in the form of fat mass (FM)] and nutritional status 
modify survival in ALS. Therefore, the assessment of FM and implementation of nutritional 
interventions to maintain FM are important components of routine care in ALS patients. 
Anthropometric measurements, including body mass index (BMI) and body adiposity index 
(BAI) are commonly used to predict adiposity in order to guide nutritional management. 
However, the accuracy of these measurements in ALS patients is currently unknown.  
 
Hypermetabolism [an increase in measured resting energy expenditure (REE) 
compared to a predicted REE] has been reported in some ALS patients and is also a 
possible modifier of disease progression. If this is a causal relationship, then strategies to 
correct or compensate for increased energy expenditure could possibly modify disease 
course. However, further studies to clarify the incidence, clinical correlations and 
consequences of hypermetabolism must be established.  
 
The objectives of this thesis were to determine whether commonly used 
anthropometric measurements are accurate predictors of FM in ALS patients and to study 
the incidence and clinical correlations of hypermetabolism in ALS patients. 
 
 
 3 
Methodology and main findings: 
 
Anthropometric measurements of BMI and BAI were compared to percentage FM derived 
from air displacement plethysmography (ADP) in 44 ALS patients and 35 age- and sex- 
matched healthy controls. Using Bland-Altman analyses it was found that both 
anthropometric measurements were less accurate predictors of FM in ALS patients than in 
controls and that BMI and BAI provided a poor estimate of FM in ALS patients. In a 
longitudinal assessment of 29 ALS patients, neither BMI nor BAI consistently reflected the 
change in FM. These results indicate that an isolated measure of BMI and BAI is not an 
accurate indicator of adiposity in ALS and that longitudinal measurements could be 
misleading. 
 
REE was measured via indirect calorimetry (mREE) and compared to a predicted 
REE (pREE, derived from a model that accounts for body composition) in 50 ALS patients 
and 50 age- and sex- matched healthy controls. Hypermetabolism was defined as a 
metabolic index (mREE/pREE x100) ≥ 120. Individuals with a metabolic index <120 were 
considered to be normometabolic. Hypermetabolism was found in 16% of controls and 
40% of ALS patients. Hypermetabolic ALS patients had a higher LMN disease burden 
(assessed by clinical examination) and a greater short-term functional decline (assessed 
by the revised ALS functional rating scale, ALSFRS-R) than normometabolic patients. 
 
Conclusions and future directions: 
 
This study found that in ALS patients, BMI and BAI are not accurate predictors of FM and 
that they provide a poor indicator of change in FM over time. It is therefore likely that 
changes in BMI and BAI in ALS patients occur independent to changes in FM alone and 
could depend on muscle atrophy and re-distribution of fat. 
 
 It was also found that when body composition is accounted for, the incidence of 
hypermetabolism is greater in ALS patients than in healthy matched controls. An 
association between hypermetabolism and LMN disease burden was observed in ALS 
patients. As LMN disease burden reflects dysfunction of motor units, it is hypothesized that 
hypermetabolism in ALS could arise from abnormal motor units which include 
dysfunctional LMNs, disrupted neuromuscular junctions and denervated muscle. 
Furthermore, hypermetabolism was associated with a greater functional decline in ALS 
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patients who were studied over time. In the light of these findings it is hypothesized that 
hypermetabolism could drive progression of ALS and lead to a vicious cycle of 
denervation, hypermetabolism and further disease progression. 
 
Overall, the results of this thesis suggest that BMI and BAI are inadequate markers 
of nutritional status in ALS and that hypermetabolism is an important metabolic 
consideration in ALS patients. More accurate ALS-specific predictors of FM are required to 
guide nutritional therapies and further clinical and physiological studies are needed to 
understand the cause and prognostic implications of changes in body composition and 
hypermetabolism. 
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Chapter 1: Introduction and review of the literature 
 
1.1 Amyotrophic lateral sclerosis 
 
1.1.1 Definition, diagnosis and clinical features 
 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by 
the degeneration and loss of upper motor neurones (UMN) and lower motor neurones 
(LMN), leading to progressive paralysis (Al-Chalabi et al., 2012). The lifetime risk is 
approximately 1 in 350 (Alonso et al., 2009), although, for unknown reasons, age and sex 
modify an individual’s risk. ALS is rare before the 4th decade of life. The incidence peaks in 
the 7th decade of life, followed by a decline in incidence in people over 80 years of age 
(Deloitte, 2015). Males have 1.5 fold greater risk of developing ALS than females, 
however, the sex ratio varies with age and males predominate in younger patient groups 
(McCombe and Henderson, 2010). A recent estimate of the prevalence of ALS in Australia 
was 8.7 per 100,000, which equates to over 2000 Australians living with ALS at any one 
time (Deloitte, 2015, Talman et al., 2016).  
 
The clinical hallmark of ALS is the concomitant presence of progressive UMN and 
LMN deficits involving the brainstem and multiple spinal cord regions. As there are 
currently no specific diagnostic tests for ALS, after exclusion of alternative causes, 
identification of this combination of clinical features is used to diagnose ALS according to 
the El Escorial diagnostic criteria (Brooks et al., 2000, Ludolph et al., 2015).  
 
There is heterogeneity in the clinical features of ALS. Clinical signs of dysfunction of 
LMNs (weakness and muscle wasting) and/or UMNs (spasticity and increased deep 
tendon reflexes) can begin in any motor region and are generally followed by involvement 
of other regions over time (Turner et al., 2010). Limb-onset disease occurs most 
commonly (in ~70% of cases), followed by bulbar-onset disease (in ~25%) and rarely, in 
~5% of cases, trunk or respiratory involvement occurs first (Ferguson and Elman, 2007). 
Individual patients also vary with regards to the relative prominence of UMN and LMN 
signs, the rate and pattern of progression and the presence of extra-motor features 
(Pradat and Bruneteau, 2006).  
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Given the clinical heterogeneity, in an attempt to classify individuals with ALS into 
meaningful clinical groups, different ‘phenotypes’ have been proposed. These 
classifications include distinctions based on the site of disease onset, predominant spinal 
level of involvement (Talman et al., 2016), and the degree of UMN and LMN clinical signs 
(Ravits et al., 2007). In most individuals with ALS, a combination of UMN and LMN signs is 
evident at diagnosis. However, rarely, individuals present with only LMN (referred to as the 
‘flail’ variant) or only UMN signs (referred to as primary lateral sclerosis or PLS). The 
distinction of these phenotypes has prognostic value as the ‘flail’ and PLS variants have a 
longer survival than other forms of ALS (Talman et al., 2016).  
 
Although defined by motor features, recent observations suggest that clinical 
involvement in ALS extends beyond the motor system (McCombe et al., 2017). Cognitive 
impairment, including behavioural, cognitive and language deficits, affect 5% of patients. 
In these patients there is significant clinical and neuropathological overlap with 
frontotemporal dementia (FTD) (Mitsuyama and Inoue, 2009, Montuschi et al., 2015). 
Given the expanding phenotype of ALS, its clinical heterogeneity (del Aguila et al., 2003) 
and the absence of specific diagnostic markers, there is often delay in its diagnosis 
(Talman et al., 2016, Knibb et al., 2016). Therefore to aid in the diagnosis of ALS, clinical 
(Brooks et al., 2000, Ludolph et al., 2015) and electrodiagnostic criteria (de Carvalho et al., 
2008) are widely employed in research and clinical settings.  
 
There are currently no curative treatments for ALS and the median survival is only 
18 months from diagnosis (Knibb et al., 2016). Neuromuscular respiratory failure is the 
commonest cause of death; therefore, non-invasive ventilation (NIV) is used in some 
patients to prolong survival and improve quality of life (Radunovic et al., 2013). Riluzole, 
an inhibitor of presynaptic glutaminergic transmission, exerts a modest survival benefit 
(Miller et al., 1996). Edaravone, an anti-oxidant approved for use in ALS patients in Japan, 
has shown some benefit in a subgroup of patients (Abe et al., 2014, Abe et al., 2017) and 
in 2017 it was approved by the United States Food and Drug Administration (Hardiman 
and van den Berg, 2017). However, given the limited benefits offered by the currently 
available drug treatments for ALS, optimal care of ALS patients focuses on symptomatic 
and palliative therapies delivered in specialized multidisciplinary clinics (Rooney et al., 
2015).  
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1.1.2 Hypotheses on pathogenesis 
Since the first descriptions of the characteristic clinical and pathological features of ALS by 
Jean-Martin Charcot in the nineteenth century (Katz et al., 2015), much has been 
elucidated regarding the cellular mechanisms that contribute to the pathogenesis of ALS. 
Proposed pathogenic mechanisms include mitochondrial dysfunction (Hervias et al., 2006, 
Muyderman and Chen, 2014), glutamate excitotoxicity (Heath and Shaw, 2002, Vucic and 
Kiernan, 2006) and abnormal protein aggregation (Mackenzie et al., 2007, Blokhuis et al., 
2013). These mechanisms are summarized in Figure 1.1. Over 20 genetic mutations have 
been implicated in the pathogenesis of ALS (Al-Chalabi et al., 2012, Renton et al., 2014). 
These include mutations in the superoxide dismutase 1 (SOD1) (Rosen et al., 1993), 
transactive response DNA binding protein (TARDBP) (Kabashi et al., 2008), fused in 
sarcoma (FUS) (Kwiatkowski et al., 2009, Vance et al., 2009) and chromosome 9 open 
reading frame 72 (C9orf72) (DeJesus-Hernandez et al., 2011) genes. However, only 10% 
of all cases are familial (Renton et al., 2014). A recent large meta-analysis suggests an 
oligogenic basis for sporadic ALS (Zou et al., 2017). 
 
Despite these genetic and molecular advances, the underlying cause of ALS is not 
fully understood. Recent theories suggest that a complex combination of genetic, 
environmental and molecular mechanisms plays a role in the development of ALS 
(Kiernan et al., 2011). Current theories propose a six-step model of disease (Al-Chalabi et 
al., 2014). However, it is possible that the multistep process leading to the development of 
ALS is variable among individuals. Although common underlying aetiologies could exist, it 
is likely that the specific combination of factors that contribute to disease could differ 
among individuals (Al-Chalabi et al., 2014). 
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Figure 1.1 Cellular and molecular processes mediating neurodegeneration in ALS 
The mechanisms underlying neurodegeneration in ALS are multifactorial and operate 
through inter-related molecular and genetic pathways. Specifically, neurodegeneration in 
ALS could result from a complex interaction of glutamate excitoxicity, generation of free 
radicals, cytoplasmic protein aggregates, SOD1 enzymes, combined with mitochondrial 
dysfunction, and disruption of axonal transport processes through accumulation of 
neurofilament intracellular aggregates. Mutations in TARDBP and FUS result in formation 
of intracellular aggregates, which are harmful to neurones. Activation of microglia results in 
secretion of proinflammatory cytokines, resulting in further toxicity. Ultimately, motor 
neurone degeneration occurs through activation of calcium-dependent enzymatic 
pathways. ALS, amyotrophic lateral sclerosis. From Kiernan et al. (Kiernan et al., 2011). 
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weakness, emotional lability, and frontal lobe-type 
cognitive dysfunction.21
In terms of presentation, UMN disturbance involving 
the limbs leads to spasticity, weakness, and brisk deep 
tendon refl exes. By contrast, LMN limb features include 
fasciculations, wasting, and weakness. Bulbar UMN 
dysfunction results in spastic dysarthria, which is 
characterised by slow, laboured, and distorted speech, 
often with a nasal quality.22 The gag and jaw jerk can 
be pathologically brisk. Bulbar LMN dysfunction can 
be identifi d by tongue wasting, weakness, and 
fasciculations, accompanied by fl accid dysarthria and 
later dysphagia. Flaccid dysarthria result  in asal 
speech caused by palatal weakness, hoarseness, and a 
weak cough.22
ALS is relentlessly progressive—50% of patients die 
within 30 months of symptom onset and about 20% of 
patients survive between 5 years and 10 years after 
symptom onset.23 Older age at symptom onset, early 
respiratory muscle dysfunction, and bulbar-onset disease 
are associated with reduced survival, whereas limb-onset 
disease, younger age at presentation, and longer diagnostic 
delay are independent predictors of pro longed survival.23
Some ALS subtypes tend to lead to a better prognosis. 
Specifi cally, fl ail-limb variant ALS (fi gure 1A, fi gure 1B) 
and progressive muscular atrophy, both predominantly 
LMN forms, are characterised by slower progression 
than other forms f ALS.23,24 In the pure bulbar palsy 
phenotype, which typically aﬀ ects women older than 
65 years of age w th disease re aining localised to 
oropharyngeal musculature and with UMN features 
predomin ting,23 the prognosis varies from 2–4 years. 
Additionally, patients with primary lateral sclerosis 
progress more slowly than do patients with classic 
Figure 2: Cellular and molecular processes mediating neurodegeneration in ALS
The mechanisms underlying neurodegeneration in ALS are multifactorial and operate through inter-related molecular and genetic pathways. Specifi cally, neurodegeneration in ALS might result 
from a complex interaction of glutamate excitoxicity, generation of free radicals, cytoplasmic protein aggregates, SOD1 enzymes, combined with mitochondrial dysfunction, and disruption of 
axonal transport processes through accumulation of neurofi lament intracellular aggregates. Mutations in TARDBP and FUS result in formation of intracellular aggregates, which are harmful to 
neurons. Activation of microglia results in secretion of proinfl ammatory cytokines, resulting in further toxicity. Ultimately, motor neuron degeneration occurs through activation of 
calcium-dependent enzymatic pathways. ALS=amyotrophic lateral sclerosis.
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1.1.3 Factors that modify survival in ALS 
 
The rate of disease progression and the length of survival in ALS are variable among 
individuals (Chiò et al., 2011). Indeed, phenotypic heterogeneity can be observed between 
individuals with the same genetic mutation (Al-Chalabi et al., 2012). Therefore there has 
been a search for factors that influence the progression of disease (Chiò et al., 2009). In 
addition to interventions such as riluzole therapy (Miller et al., 1996) and NIV (Radunovic 
et al., 2013), a number of patient and disease factors have been found to affect prognosis 
(Knibb et al., 2016).  
 
Older age and bulbar involvement at disease onset (Chiò et al., 2009), cognitive 
impairment (Elamin et al., 2011), LMN dysfunction (Devine et al., 2016) and respiratory 
muscle weakness (Pinto et al.) predict a shorter survival time. There are also some genes 
that modify the clinical course of ALS (Meyer et al., 2005, Fogh et al., 2016, Lopez-Lopez 
et al., 2014, Taylor et al., 2016). In the absence of a cure, discovery of factors that modify 
disease progression is critical. An understanding of processes that influence the course of 
ALS could shed light on disease mechanisms and identify therapeutic targets that can be 
manipulated in order to prolong survival.   
 
1.1.4 Metabolism as a modifier of ALS  
 
Systemic energy metabolism is emerging as an important modifying factor in ALS and is 
the focus of this thesis. Mounting evidence suggests that alterations in metabolism can 
affect the development and progression of disease. The following sections will discuss this 
in detail.  
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1.2 Metabolic dysfunction in ALS 
 
A version of this section of the thesis was published in IOANNIDES, Z. A., NGO, S. T., 
HENDERSON, R. D., MCCOMBE, P. A. & STEYN, F. J. 2016. Altered Metabolic 
Homeostasis in Amyotrophic Lateral Sclerosis: Mechanisms of Energy Imbalance and 
Contribution to Disease Progression. Neurodegener Dis, 16, 382-397. This paper can be 
found in Appendix 1. 
 
Increasing evidence suggests that altered metabolic homeostasis occurs in some 
ALS patients and could modify the course of ALS. Reduced body energy stores in the form 
of fat mass (FM) (Nau et al., 1995, Kasarskis et al., 1996, Desport et al., 1999, Desport et 
al., 2000, Jawaid et al., 2010a, Paganoni et al., 2011) and increased resting energy 
expenditure (REE) (Kasarskis et al., 1996, Desport et al., 2001, Desport et al., 2005, 
Bouteloup et al., 2009, Funalot et al., 2009, Kasarskis et al., 2014) appear to be of clinical 
importance in some ALS patients. The evidence that metabolic needs increase relative to 
disease severity and duration in ALS (Kasarskis et al., 1996) suggests that the 
pathological changes that occur with worsening disease could contribute to altered energy 
needs.  
 
It appears that the interplay between pathogenic mechanisms and physiological 
responses to ALS results in a state of chronic negative energy balance that worsens 
patient prognosis [reviewed in (Dupuis et al., 2011, Ahmed et al., 2016b)]. It is therefore 
possible that modification of the metabolic imbalance could improve patient outcome and 
provide a therapeutic target in ALS. However, to develop effective treatment strategies 
that improve metabolic homeostasis, prognosis and quality of life for ALS patients, it is first 
necessary to understand the mechanisms of dysregulated metabolism and the impact on 
the disease process.  
 
This section of the thesis presents the evidence for altered energy balance in ALS, 
focusing on alterations in body composition and REE. Underlying mechanisms that could 
affect energy balance and affect disease progression are discussed and summarised in 
Figure 1.2. Possible therapeutic strategies that could improve metabolic imbalance and 
modify the course of ALS are also considered. 
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Figure 1.2 Possible mechanisms of altered energy balance in ALS: This shows factors 
that could potentially lead to altered energy balance in ALS. Factors which could reduce 
energy supply are displayed on the left in green and factors which could increase energy 
expenditure are displayed on the right in red. This combination of reduced energy supply 
in parallel with increased energy demand create an energy deficit, which could be linked to 
a more rapid disease progression and a poorer outcome in ALS. Abbreviation: RR, 
respiratory rate. 
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1.2.1 Reduced energy stores in ALS 
 
Fat mass in ALS 
A large body of evidence suggests that there is an association between endogenous 
energy stores in the form of FM, and the development and progression of ALS. Increased 
body fat before the diagnosis of ALS is associated with a prolonged survival (Gallo et al., 
2013). It has been found that ALS patients are generally lean, and they are more likely to 
report premorbid slimness or athleticism (Scarmeas et al., 2002).  
  
 A decline in body mass and FM occurs throughout the course of ALS (Nau et al., 
1995, Kasarskis et al., 1996, Desport et al., 1999, Desport et al., 2000, Jawaid et al., 
2010a) and a more rapid rate of reduction in adiposity predicts a worse survival (Stambler 
et al., 1998, Shimizu et al., 2012). Furthermore, the observation of markedly reduced 
amounts of white adipose tissue in the SOD1 mouse (a widely studied preclinical model of 
ALS) in the asymptomatic phase of disease suggests that loss of FM could occur early in 
the disease process (Dupuis et al., 2004).  
  
Clinical studies have found that adiposity, measured as FM, is a predictor of 
mortality (Gallo et al., 2013, Lindauer et al., 2013), disease progression (Shimizu et al., 
2012), and survival (Paganoni et al., 2011) in ALS patients. Body mass index (BMI), a 
widely used surrogate marker of adiposity, is an independent predictor of survival in ALS 
(Paganoni et al., 2011). Paganoni et al found a ‘U-shaped’ relationship between survival 
and BMI. The lowest mortality was seen in patients who were mildly obese [BMI 30–35, 
World Health Organisation (WHO) obese class I (WHO, 1995)]  In contrast, mortality was 
highest in underweight patients (BMI ≤18.5) (Paganoni et al., 2011) (Figure 1.3). Similarly, 
Shimizu et al, observed a shorter survival in ALS patients who experienced a more rapid 
rate of reduction in BMI (Shimizu et al., 2012), and Stambler et al observed a shorter 
survival in ALS patients with greater weight loss (Stambler et al., 1998). Taken together 
these findings suggest that body energy stores, in the form of FM, could be associated 
with survival in ALS.  
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Figure 1.3 Kaplan–Meier survival curves of 427 ALS patients stratified according to 
their BMI. Censored patients are indicated by crosses on the corresponding survival 
curve. The greatest survival probability occurred in patients who were mildly obese (BMI 
30–34.99) and the lowest survival probability was in underweight patients (BMI ≤18.5). 
Blue line: BMI≤18.5; red line: BMI 18.5–24.99; green line: BMI 25–29.99; brown line: BMI 
30–34.99; purple line: BMI 35–39.99, light green line: BMI >40 (log rank, p = 0.00055). 
Adapted from Paganoni et al. (Paganoni et al., 2011). Abbreviation: BMI, body mass 
index. 
 
 
 
 
 
 
variable did not satisfy the proportional hazards
assumption. The linear relationship between BMI
and survival was tested by including the quadratic
term BMI2 as a covariate.
RESULTS
A total of 427 subjects from three studies were
included in our analysis (Table 1). There were no
significant differences in baseline demographics
among the three included studies. The single-cen-
ter prospective cohort was followed significantly
longer than the other studies and therefore had a
higher rate of mortality.
We hypothesized that cholesterol levels would
change with disease progression over time, specifi-
cally that LDL levels would decrease and HDL lev-
els would increase due to weight loss and declining
FVC.2,10,11 As shown in Table 2, cholesterol levels
were essentially unchanged despite a predictable
but small decline in BMI and a strong decline in
FVC and ALSFRS-R.
Next, when a survival analysis was performed
dividing subjects into LDL/HDL ratios <2.99 or
>2.99, there was a trend toward significance (log
rank: P ¼ 0.075; see Supplementary Material Fig.
S1). More interestingly, when the LDL/HDL ratio
was stratified into quartiles, the log-rank test for
equality over strata was significant (P ¼ 0.031; Fig.
1A). However, as shown in Table 3, there were signif-
icant differences in BMI, ALSFRS-R, and age across
the quartiles and, after adjusting for each of these
variables, the lipid ratio variable (LDL/HDL ratio)
was no longer significantly associated with survival.
Our final multivariate proportional hazards
model using stepwise selection did not include any
cholesterol variables (Table 4; in Supplementary Ma-
terial, Table S1, the lipid ratio and ALSFRS-R have
been forced into the model). Higher BMI, higher
FVC, and younger age were associated with improved
survival (Fig. 1B and data not shown), and each of
these variables was co-linear with the lipid ratio.
BMI was significantly associated with survival
even after adjusting for disease severity, including
ALSFRS-R, FVC, time since symptom onset, time
since diagnosis, and bulbar onset, with a dose-de-
pendent increase in survival for each unit of BMI
(adjusted hazard ratio 0.86, confidence interval
0.80–0.93, P ¼ 0.0001; Fig. 1B and Table 4). The
second-order term (BMI2) was also significant,
showing that there is a U-shape to the survival
curve, with the maximum survival time seen in sub-
jects with BMI 30–35 (WHO obese class I) (Fig.
1C). A sensitivity analysis was performed, excluding
subjects from the Trial of Topiramate in ALS given
the potential side effect of weight loss of this medi-
cation, which indicated that the differences across
strata were still significant (log rank: P ¼ 0.001).
DISCUSSION
The role of cholesterol metabolism in amyotrophic
lateral sclerosis (ALS) has been an area of interest
since Dupuis et al. suggested that dyslipidemia
FIGURE 1. Correlation between lipid levels, BMI, and survival
in ALS. Kaplan–Meier survival curves of 427 ALS patients
stratified according to their LDL/HDL ratio (A) or BMI (B). Cen-
sored patients are indicated by crosses on the corresponding
survival curve. The survival curves were truncated at 764 days
(the maximum time of follow-up in the Topiramate study). (A)
Blue line: LDL/HDL ratio "1.82; red line: LDL/HDL ratio 1.83–
2.27; green line: LDL/HDL ratio 2.28–2.95; brown line: LDL/
HDL ratio >2.95 (log rank: P ¼ 0.031). (B) Blue line: BMI
"18.5; red line: BMI 18.5–24.99; green line: BMI 25–29.99;
brown line: BMI 30–34.99; purple line: BMI 35–39.99, light
green line: BMI >40 (log rank, P ¼ 0.00055). (C) Bar graph of
percent mortality by BMI class show U-shaped relationship
between unadjusted all-cause mortality and BMI. The nadir for
all-cause mortality was seen at BMI ¼ 30–35. N ¼ total number
at risk by BMI class. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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Nutritional interventions 
Studies that showed benefits following nutritional interventions that increase energy supply 
in ALS patients provide further evidence of an association between energy stores and 
progression of ALS. It has been shown that hypercaloric oral food supplementation 
(provision of more calories than would normally be recommended) can stabilize or 
moderately increase body weight (Dorst et al., 2013) and increase arm muscle area and 
circumference (Silva et al., 2010) in ALS patients. These results suggest that as well as 
maintaining FM, dietary supplementation could also prevent loss of muscle mass in ALS 
patients.  
 
Given the association between loss of adiposity and poorer survival (Paganoni et 
al., 2011, Shimizu et al., 2012, Gallo et al., 2013, Lindauer et al., 2013), there is increasing 
interest in the maintenance of FM in ALS via invasive nutritional interventions (Mazzini et 
al., 1995 27, Muscaritoli et al., 2012, Wills et al., 2014). Nutritional supplementation is a 
rapidly emerging area in the field of ALS therapeutics (Rosenfeld and Ellis, 2008) and 
enteral nutrition has become an important aspect of therapy in some ALS patients. 
 
Gastrostomy feeding, the most common route of delivery of enteral nutrition, has 
been shown to improve survival (Wills et al., 2014) and enhance quality of life (Mazzini et 
al., 1995) in ALS patients. The American Academy of Neurology (Miller et al., 2009) and 
the European Federation of Neurological Societies (Andersen et al., 2012) recommend 
gastrostomy, particularly in patients who have bulbar involvement. Gastrostomy is 
therefore widely used in ALS patients who develop dysphagia (ProGas, 2015).  
 
Although increasing clinical evidence suggests that oral (Silva et al., 2010, Dorst et 
al., 2013) and enteral (Mazzini et al., 1995, Wills et al., 2014, Dorst et al., 2015) nutritional 
supplementation are beneficial in ALS, a balance between maintaining weight and 
avoiding excess gain of fat must be achieved. In most populations, excessive weight gain 
is detrimental to cardiovascular health (Poirier et al., 2006). Furthermore, in ALS patients, 
excessive weight gain could impair respiratory muscle function or increase carer burden 
during passive mobilization of paralyzed patients (Héritier et al., 2015).  
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In order to optimize nutritional management, accurate measures of adiposity are 
vital. Quantification of FM provides information regarding the body’s storage of energy. In 
conjunction with biochemical markers of nutrition (Zazra, 1997), this information is critical 
in guiding nutritional management, particularly in patients who are receiving oral 
supplementation or enteral nutrition (Heffernan et al., 2004). Anthropometric predictors, for 
example BMI and body adiposity index (BAI), are commonly used in clinical practice to 
estimate FM due to their practicality, but it is unknown whether anthropometric predictors 
of FM are accurate in ALS patients. This is clinically important as anthropometric 
predictors are used to guide nutritional management, which could improve outcomes in 
ALS patients (Silva et al., 2010, Dorst et al., 2013, Wills et al., 2014). Therefore, 
assessment of the accuracy of anthropometric predictors of FM in ALS is warranted. 
 
 
 Reduced food intake 
Inadequate energy intake is likely to contribute to the weight loss that occurs in ALS 
patients. Food intake is governed by appetite and the capacity to consume and digest 
food. These factors could be affected in ALS as a result of anorexia, fatigue, dysphagia, 
respiratory dysfunction and upper limb weakness. Additionally, cognitive impairment, 
which occurs in up to 50% of ALS patients (Murphy et al., 2016), could impair an 
individual’s capacity to plan meals, obtain ingredients and prepare meals.  
 
Appetite is regulated by central neuronal circuits in the hypothalamus, brainstem 
and limbic system, as well as peripheral organs including the gastrointestinal tract and 
adipose tissue (Ahima and Antwi, 2008). The ‘gut-brain’ connection refers to the release, 
in response to food intake, of neuropeptides and hormones that act in the brain to alter 
hunger and satiety (Ahima and Antwi, 2008). In health, this system maintains metabolic 
homeostasis by balancing energy intake and storage; however, considerable evidence 
suggests that these processes are impaired in ALS (Slowie et al., 1983, Kasarskis et al., 
1996, Vaisman et al., 2009). Indeed, anorexia is frequent in subjects with ALS, and reports 
indicate a deficit of calorie consumption in ALS patients that ranges from 70% (Slowie et 
al., 1983) to 84% (Kasarskis et al., 1996) of recommended daily energy needs.  
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Poor nutritional status is negatively associated with disease severity in ALS, and the 
intake of nutrients tends to decrease as disease progresses (Park et al., 2015b). In ALS, 
anorexia and malnutrition is likely to be driven by multiple neuroendocrine and physical 
factors. For example, a reduction in ghrelin, a hormone that stimulates appetite (Kojima 
and Kangawa, 2002), is seen in ALS (Ngo et al., 2015, Czell et al., 2015) and 
administration of ghrelin to the SOD1 mouse model of ALS prolongs survival through 
increased calorie intake (Matsuo T, 2013). It could be argued that ghrelin promotes 
survival through stimulating appetite, however this remains untested.  
 
Recent observations show that ALS could be associated with dysfunction of 
processes that would normally regulate food intake. Treatment with pioglitazone in ALS 
patients and the SOD1 mouse failed to promote weight gain, despite confirmation of 
peripheral action of pioglitazone (Vercruysse et al., 2016). Pioglitazone normally promotes 
food intake via the central melanocortin system, a key hypothalamic neuronal network 
known to regulate food intake and metabolism (Sohn, 2015). Therefore, a lack of weight 
gain in ALS patients and mice treated with pioglitazone suggests possible dysfunction of 
this system.  
 
Indeed, interrogation of multiple mouse models of ALS (harbouring mutations for 
SOD, TARDP and FUS genes) confirmed altered abundance and/or expression of two key 
hypothalamic regulators of food intake, proopiomelanocortin (POMC) and agouti-related 
protein (AgRP) (Vercruysse et al., 2016). Additionally, impairments in serotonin-mediated 
POMC activity were observed in the SOD1 mouse (Vercruysse et al., 2016). This also 
suggests that in ALS there could be impairment of neuronal circuitry that regulates food 
intake and calorie balance. Collectively, these observations suggest that calorie imbalance 
in ALS could occur as a consequence of defects in central processes that regulate 
appetite. 
 
Irrespective of the mechanism in ALS, the failure to consume sufficient calories to 
meet energy needs could result in energy deficit, which could exacerbate weakness and 
fatigue, thus further impairing nutrient intake to create a ‘vicious cycle’ of suboptimal 
energy supply.   
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1.2.2 Altered energy expenditure in ALS 
 
Hypermetabolism in ALS 
In addition to the reduced energy intake discussed above, another plausible contributor to 
the loss of energy stores in ALS is an increase in resting energy expenditure (REE) known 
as hypermetabolism.  
 
REE reflects the energy required to maintain vital functions in a fasted state. In 
healthy adults, REE accounts for up to 75% of overall energy expenditure and is highly 
variable among individuals (Donahoo et al., 2004). REE is determined by body 
composition, predominantly fat free mass (FFM) (Johnstone et al., 2005), the metabolically 
active component of the body that includes muscle and other organs. A deviation of the 
measured REE (mREE) from predicted REE (pREE) can be in the direction of 
hypometabolism (i.e. when the mREE is lower than the pREE) or hypermetabolism (i.e. 
when the mREE is greater that the pREE).  
 
Hypermetabolism has been reported in mouse models of ALS (Dupuis et al., 2004, 
Niessen et al., 2007) and ALS patients (Kasarskis et al., 1996, Desport et al., 2001, 
Desport et al., 2005, Bouteloup et al., 2009, Funalot et al., 2009, Kasarskis et al., 2014) 
(patient studies are compared in table 1.1). Hypermetabolism in ALS can be considered 
paradoxical because loss of FFM secondary to neurogenic muscle wasting (Nau et al., 
1995, Kasarskis et al., 1996, Desport et al., 1999, Desport et al., 2000, Jawaid et al., 
2010a) would be expected to reduce REE (Johnstone et al., 2005).  
 
However, it is important to note that existing studies of hypermetabolism in ALS 
(Kasarskis et al., 1996, Desport et al., 2001, Desport et al., 2005, Bouteloup et al., 2009, 
Funalot et al., 2009, Kasarskis et al., 2014) have limitations. These reports of 
hypermetabolism have been derived by comparing the mREE to the pREE calculated from 
the Harris-Benedict equation, which is an estimate that could be misleading in individuals 
with ALS as it does not consider body composition (Weijs, 2011). The limitations of pREE 
models are discussed in detail in Chapter 2 section 2.2.1. 
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Additionally, the existing studies of hypermetabolism in ALS consider an individual 
to be hypermetabolic when the mREE is ≥ 110% of the pREE (Kasarskis et al., 1996, 
Desport et al., 2001, Desport et al., 2005, Bouteloup et al., 2009, Funalot et al., 2009, 
Kasarskis et al., 2014). However, studies of patients with other diseases such as insulin 
resistance, diabetes and liver cirrhosis, in whom hypermetabolism is common (Muller et 
al., 1993), often use a stricter threshold to indicate hypermetabolism; a mREE ≥ 120% of 
the pREE (Muller et al., 1999, Perseghin et al., 2002). It is currently unknown how the use 
of this stricter threshold could affect studies of hypermetabolism in ALS patients.  
 
Furthermore, although hypermetabolism has been suggested to occur early in ALS 
(Dupuis et al., 2004, Niessen et al., 2007, Bouteloup et al., 2009), it is notable that the 
majority of reports of hypermetabolism are in patients with low revised ALS Functional 
Rating Scale (ALSFRS-R) scores which indicate more advanced disease (see table 1.1). 
Therefore, it is not clear when hypermetabolism becomes apparent during the course of 
ALS, and it is yet to be determined which individuals with ALS are at risk of becoming 
hypermetabolic. Additionally, few studies in ALS include age- and sex-matched healthy 
controls as a comparison group, potentially biasing the conclusions. These are important 
considerations that need to be clarified before attempting to compensate for increased 
energy demands. 
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Table 1.1 Predictions of hypermetabolism in ALS.  
Study Partic-ipants 
ALSFRS-
R 
Method of 
prediction 
Prevalence 
of hyper-
metabolism 
relative to 
predicted 
REE 
Prevalence 
of hyper-
metabolism 
relative to a 
matched 
control 
population 
Additional key study 
findings 
Kasarskis 
et al. 1996 
(Kasarskis 
et al., 
1996) 
16 ALS,  
0 cons 
 
N/A mREE 
measured 
by IC 
compared 
to pREE 
from HB* 
Repeated 
measures 
for 12 
subjects 
(serial 
measures 
for an 
individual 
were 
averaged) 
4 of 16 (25%) 
 
N/A • Progressive reductions 
in BMI and FM relative 
to proximity to death 
• mREE/pREE increased 
as death approached 
Desport et 
al., 2001 
(Desport 
et al., 
2001) 
62 ALS,  
31 cons 
 
29.0+/-7.0 Mean 
mREE from 
IC 
compared 
between 
ALS group 
and control 
group. 
mREE 
measured 
by IC 
compared 
to pREE 
from HB in 
ALS group* 
42 of 62 
(67.8%) 
Mean mREE 
of ALS group 
was 10.1% 
greater than 
the control 
group (p = 
0.03) 
Prevalence 
of hyper-
metabolism 
in each 
group not 
presented 
• No correlation between 
mREE and FVC, 
fasciculation or 
spasticity scores in ALS 
group 
• mREE remained stable 
as ALS subjects 
approached death (in 
contrast to (Kasarskis 
et al., 1996) 
Desport et 
al., 2005 
(Desport 
et al., 
2005) 
168 
ALS,  
0 cons 
28.0+/-7.1 mREE 
measured 
by IC 
compared 
to pREE 
from HB* 
Repeated 
measures 
for 44 
subjects 
105 of 168 
(62.3%) 
N/A • mREE correlated with 
age, sex, phenotype, 
malnutrition, weight, 
FFM, and ALSFRS 
• FFM or mREE, 
corrected for FFM, did 
not decrease relative to 
proximity to death (in 
contrast to (Kasarskis 
et al., 1996) 
Funalot et 
al., 2009 
(Funalot 
et al., 
2009) 
11 
FALS,  
33 
SALS,  
0 cons 
27.6+/-7.3 
in FALS 
group 
 
29.2+/-6.6 
in SALS 
group 
mREE 
measured 
by IC 
compared 
to pREE 
from HB* 
 
11/11 (100%) 
in FALS 
group 
17/33 (52%) 
in SALS 
group 
N/A • mREE in FALS patients 
was not influenced by 
the degree of 
neurological or 
respiratory involvement 
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Bouteloup 
et al., 
2009 
(Boutelou
p et al., 
2009) 
61 ALS, 
no cons 
30.7+/-4.8 mREE 
measured 
by IC 
compared 
to pREE 
from HB* 
Repeated 
measures 
for 45 
subjects 
 
29/61 
(47.5%) 
N/A • mREE did not change 
over time, despite 
deteriorating 
neurological, nutritional 
and respiratory 
parameters 
Kasarskis 
et al., 
2014 
(Kasarskis 
et al., 
2014) 
80 ALS,  
0 cons 
35.7+/-5.5 TDEE 
measured 
directly by 
using the 
doubly 
labeled 
water 
method 
and mREE 
measured 
by IC 
Did not 
present the 
prevalence of 
hyper-
metabolism 
N/A • Highlighted the 
variation between 
equations to predict 
cREE 
• Physical function and 
body composition are 
key when estimating 
TDEE 
Notes: *Subjects considered hypermetabolic when mREE ≥ 110% of pREE. Abbreviations: ALSFRS-R, 
Revised Amyotrophic lateral sclerosis functional rating scale; BMI, body mass index; FALS, familial ALS; 
cons, control subjects; FFM, fat free mass; FM, fat mass; FVC, forced vital capacity; HB, Harris-Benedict 
equation; IC, Indirect calorimetry; mREE, measured resting energy expenditure; N/A, not assessed; pREE, 
predicted REE; SALS, sporadic ALS; TDEE, total daily energy expenditure. 
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Activity and diet dependent energy needs 
Other aspects of energy requirement could also be altered in ALS. Total daily energy 
expenditure (TDEE) is a composite of REE, activity-dependent energy expenditure, and 
the thermogenic effect of food (TEF), which reflects the energy required to digest, process 
and absorb nutrients (D'Alessio et al., 1988). It is well recognised that TDEE varies greatly 
among individuals with ALS; TDEE may exceed measured REE by 2000 kilocalories per 
day (kcal/day) in some individuals, whereas TDEE may equal REE in other individuals 
(Kasarskis et al., 2014).  
 
A possible explanation for this variation in TDEE could be the variability in physical 
activity among individuals with ALS. This variability would be expected to depend on 
whether there is lower limb weakness, which impairs mobility. Furthermore, fatigue, which 
is common in ALS (Lou, 2008) and correlates with disease severity (McElhiney et al., 
2009), can also affect physical activity and therefore could also alter TDEE in ALS.  
 
Another potential explanation for the heterogeneity of TDEE in ALS is a change in 
TEF. TEF represents up to 15% of TDEE. While TEF varies relative to body weight (Reed 
and Hill, 1996, Gepner et al., 2015) and physical activity (Stob et al., 2007), it is also 
dependent on gastrointestinal motor function and autonomic nervous system activation 
(Stob et al., 2007). Although gastrointestinal abnormalities are not universally recognised 
in ALS, there are reports of weight loss (Jawaid et al., 2010a), decreased gastric motility 
(Toepfer et al., 1999a) and dysfunction of the autonomic nervous system (Baltadzhieva et 
al., 2005) in some ALS patients, which could affect the TEF.  
 
 
Altered lipolysis 
The findings of reduced FM in ALS patients (Paganoni et al., 2011) and reduced adipose 
tissue accumulation in animal models of ALS (Dupuis et al., 2004) have sparked the 
hypothesis that there is altered lipolysis in ALS. Lipolysis is the process of catabolism of 
cellular lipid droplets to generate free fatty acids (FFA), which are essential energy 
substrates (Lass et al., 2011). Lipolysis occurs predominantly in adipose tissue and is 
regulated by a number of enzymes and hormone signaling pathways (Lass et al., 2011). 
The hypothesis that lipolysis is increased in ALS is supported by the finding of elevated 
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plasma FFA in patients with ALS (Mueller and Quick, 1970, Pradat et al., 2010) as well as 
an increased rate of lipolysis (Dodge et al., 2013) and reduced FFA uptake and storage 
(Dupuis et al., 2004) in animal models of ALS.  
 
In addition to accelerated lipolysis, there is evidence that use of glycogen (an 
important alternative fuel reserve stored in liver and skeletal muscle which yields glucose 
molecules) is decreased in ALS. In SOD1 mice, there appears to be a switch in muscle 
energy use towards lipid oxidation, rather than glucose utilization, resulting in glycogen 
accumulation (Palamiuc et al., 2015).  
 
Increased glycogen storage in the central nervous system (CNS) and peripheral 
tissues of SOD1 mice (Dodge et al., 2013), and glycogen accumulation in neurones and 
glial cells of grey and ventral white matter of human ALS spinal cord (Dodge et al., 2013) 
are also indicative of reduced glucose metabolism and increased lipolysis. At the hormonal 
level, increased levels of tumor necrosis factor alpha, which induces lipolysis, (Rondinone, 
2006), and increased levels of adiponectin, which regulates glucose and fatty acid 
oxidation (Rondinone, 2006), have been detected in ALS patients (Ngo et al., 2015).  
 
An increase in lipolysis could deplete endogenous fat stores and result in reduced 
FM as seen in ALS (Nau et al., 1995, Kasarskis et al., 1996, Desport et al., 1999, Desport 
et al., 2000, Jawaid et al., 2010a). This could result in depletion of endogenous energy 
supply to neurones. This is significant because it implies that maintaining fat stores in 
order to provide FFA as an alternative energy substrate in ALS patients could improve 
energy supply to neurones and therefore potentially improve neuronal survival. 
 
Muscle atrophy and denervation 
Animal studies suggest that muscular atrophy secondary to denervation can alter systemic 
energy needs (Nunes and de Mello, 2005). In rats, denervation of skeletal muscle is 
associated with a reduction in glucose uptake, glycogen synthesis and insulin sensitivity 
(Nunes and de Mello, 2005). Denervation atrophy in the SOD1 mouse leads to diminished 
entry of pyruvate into the Krebs cycle, thus hampering glucose oxidation in skeletal muscle 
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(Palamiuc et al., 2015). Moreover, muscular atrophy is associated with a reduction in the 
expression of glucose transporters (Henriksen et al., 1991, Coderre et al., 1992). While yet 
to be confirmed, it is feasible that widespread and synchronous denervation of muscle and 
accompanying muscle atrophy in ALS could underlie many of the metabolic changes 
observed in patients. 
 
Respiratory failure 
Patients with ALS experience varying degrees of respiratory muscle weakness (Gay et al., 
1991). Decline in respiratory function eventually leads to hypercapnia, which is associated 
with an increase in respiratory rate and reduced survival (Czudaj et al., 2009). It is 
plausible that an increased respiratory rate in some ALS patients could increase energy 
requirements at rest and during periods of exertion. However, contrary to this theory, 
mREE does not appear to correlate with alterations in forced vital capacity (FVC, a 
standard clinical measure of respiratory function) in ALS patients (Desport et al., 2005, 
Bouteloup et al., 2009). As mild to moderate respiratory muscle weakness may not be 
detected by measuring FVC alone, a more sensitive measure such as the maximal sniff 
nasal inspiratory pressure (SNIP) (Lyall et al., 2001), might better correlate with REE but 
has yet to be studied in relation to energy expenditure in ALS patients. 
 
 
Neuronal hyperexcitability  
Neurones are metabolically active cells as energy is required to transport proteins along 
axons and for the active transfer of ions across the cell membrane to support excitability 
and conduction of impulses (Ashrafi et al., 2017). Given their high-energy demands, 
neurones are vulnerable to damage when in a state of energy restriction (Shaw and 
Eggett, 2000, Ashrafi et al., 2017).  
 
Abnormally increased excitability of motor neurones, also known as 
hyperexcitability, is proposed to play a role in the pathophysiology of ALS (Vucic and 
Kiernan, 2006, Vucic et al., 2008). Maintenance of the neuronal cell resting potential is an 
active process requiring the hydrolysis of adenosine triphosphate (ATP) via the Na+/K+- 
ATPase (Lodish et al., 2000). Hyperexcitable neurones have an increased Na+ influx, thus 
maintenance of the resting potential in a hyperexcitable neurone requires the hydrolysis of 
excessive cellular ATP. Although, it is not known how this increased ATP use (via the 
Na+/K+- ATPase) affects overall cellular energy balance in hyperexcitable neurones, it is 
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plausible that it results in increased cellular energy use. This increased energy 
requirement could exacerbate neuronal dysfunction and, if widespread, could contribute to 
an overall whole body increase in energy requirements. 
 
Neuronal repair and inflammation 
The processes of neuronal repair in ALS could significantly affect total energy 
requirements. In ALS, loss of lower motor neurons (LMN) leads to denervation of muscle 
fibres. In muscle, this results in the production of a range of factors that are trophic for 
motor axons (Henderson et al., 1983), including insulin-like growth factors (Day et al., 
2001, Shavlakadze et al., 2005) and myogenic regulatory factors (Walters et al., 2000). 
Denervated muscle cells undergo a change in the expression of genes encoding cell cycle 
regulators and extracellular matrix components (Batt et al., 2006). Denervated muscle 
cells also secrete immune molecules (interleukins) and metabolic factors (Pedersen, 
2011).  
 
These responses lead to the sprouting of new axons and re-innervation of muscle 
fibres by axons from other motor units. Successful re-innervation during the early stages of 
ALS is demonstrated by the neurophysiological finding of large motor units in ALS patients 
(Duleep and Shefner, 2013), but as disease progresses there is a failure in adequate re-
innervation, followed by muscle atrophy (Bonaldo and Sandri, 2013). In the event of mass 
synchronous denervation, as seen in ALS, the energy costs associated with collateral re-
innervation would be significant and could contribute to increased neuronal energy 
demand.  
 
Neuro-inflammatory mechanisms that serve to protect and repair dying motor 
neurones in ALS are poorly understood, however, they are likely to be energy expensive. 
A number of neuroprotective models have been proposed including those involving CD4+ 
effector T cells which modulate the central microglial and astrocytic response to injury 
(Beers et al., 2008, Jones et al., 2015).  
 
As well as being part of a protective response, neuro-inflammation can have a 
direct pathogenic effect in ALS [reviewed in (McCombe and Henderson, 2011)]. For 
example, microglial dysregulation (Beers et al., 2006) and increased pro-inflammatory 
markers have been observed in mouse models of ALS (Hensley et al., 2003) and in ALS 
patients (Ngo et al., 2015). Therefore, inflammation could play a role in both protective and 
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pathogenic mechanisms in ALS. This is an important consideration in energy balance as 
inflammation is associated with alterations in metabolic activity characterized by increased 
energy demands, which can lead to fundamental shifts in metabolism (Kominsky et al., 
2010). In this way, chronic inflammation in ALS could contribute to escalating energy 
demands in patients.  
 
Altered cortical metabolism 
With evidence of altered cortical function in over 50% of ALS patients (Murphy et al., 
2016), it is possible that a change in brain metabolism could contribute to altered energy 
needs in ALS patients. Indeed, positron emission tomography studies in ALS patients 
have demonstrated alterations in brain glucose metabolism in regions beyond the motor 
cortex (Dalakas et al., 1987, Hatazawa et al., 1988, Ludolph et al., 1992, Cistaro et al., 
2012, Pagani et al., 2014).  
 
The importance of altered cortical metabolism in changing energy needs in ALS is 
unclear at present because both increased and decreased glucose utilization in the CNS 
are reported (Dalakas et al., 1987, Hatazawa et al., 1988, Ludolph et al., 1992, Cistaro et 
al., 2012, Pagani et al., 2014). It is plausible that increased use of glucose by neurones, 
astrocytes or microglia, could increase brain metabolic activity and contribute to increased 
resting energy requirements; however, this requires further evaluation and remains 
speculative. 
 
Alterations in the gut  
In addition to alterations in energy expenditure, abnormal gut function could also affect 
energy balance in ALS. Optimal absorption of nutrients requires an intact gastrointestinal 
tract, a functioning enteric nervous system (ENS), and a healthy gut microbiome. 
Observations that the ENS and the CNS share common structural and chemical features 
(Gershon, 1997, Gershon, 1999), and that gastrointestinal dysfunction occurs in 
neurodegenerative diseases including Parkinson’s disease (Jost, 2010) and Huntington’s 
diseases (van der Burg et al., 2011), support the hypothesis that gastrointestinal 
alterations could occur in ALS, thereby altering the absorption of energy.  
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Links between the motor system and the ENS have been found in animal models. A 
lack of glial cell-derived neurotrophic factor (GDNF, a potent protective factor for motor 
neurons) in a mouse model leads to considerable loss of ENS neurones (Sanchez et al., 
1996). The TARDBP mouse model of ALS exhibits intestinal dysfunction characterised by 
a progressively thinned colon, swollen small intestine and increased TDP-43 protein 
accumulation in the myenteric nerve plexus, which contributes to death independent of 
muscular weakness (Guo et al., 2012, Hatzipetros et al., 2014). Furthermore, the receptor 
tyrosine kinase Ret, which transduces GDNF signaling, is highly expressed by a specific 
subtype of enteric neurones in the human ENS (Luesma et al., 2014).  
 
Autonomic dysfunction has been described in ALS patients (Baltadzhieva et al., 
2005), with reports of subclinical gastrointestinal motor dysfunction (Toepfer et al., 1999a), 
delayed colonic transit times (Toepfer et al., 1997), delayed gastric emptying (Toepfer et 
al., 1999b), and an increased prevalence of constipation (Nubling et al., 2014).  
Furthermore, a study of percutaneously fed ALS patients found that 7 of 10 experienced 
weight loss that was unexplained by dysphagia, hypermetabolism or inadequate diet 
(Zhang, 2011). This further implicates malabsorption as a potential mechanism for weight 
loss in ALS.  
 
Another important consideration in the absorption of nutrients is the gut microbiome, 
which comprises up to 100 trillion microorganisms (Backhed et al., 2005) that provide 
beneficial functions including nutrient absorption, vitamin synthesis and digestion of fiber 
(Maslowski and Mackay, 2011). The composition of the gut microbiome is influenced by 
diet, and gut microbes play a role in modulating inflammatory and immune responses 
(Kranich et al., 2011, Maslowski and Mackay, 2011), susceptibility to infection, and 
regulation of weight and nutrition (Kau et al., 2011, Turnbaugh and Gordon, 2009, 
Goodrich et al., 2014). Alterations in the gut microbiome could also potentially contribute to 
alterations in host metabolism (Goodrich et al., 2014, Guinane and Cotter, 2013). Whether 
this is the case in ALS is yet to be explored.  
 
In the SOD1 mouse model of ALS abnormal intestinal permeability, associated with 
increased inflammatory cytokines in the gut and an altered gut microbiome, has been 
observed (Wu et al., 2015b). Furthermore, correction of the gut microbiome with butyrate 
in this model has been shown to restore gut integrity and prolong survival (Zhang et al., 
2017). While gut microbes have not been studied in ALS patients, it is plausible that the 
 39 
dietary changes that occur in ALS (Slowie et al., 1983, Kasarskis et al., 1996) could 
contribute to adaptations in the gut microbiome. Moreover, autonomic dysfunction in ALS 
(Baltadzhieva et al., 2005) could contribute to altered bowel transit times, thereby affecting 
microbial growth and diversity (Kamada and Kao, 2013).  
 
Via these mechanisms, the microbiome could serve as a link between dietary 
intake, energy metabolism and disease state in ALS. Indeed, it has been proposed that 
gut microbes are important in the development and progression of other 
neurodegenerative diseases (Wang and Kasper, 2014, Scheperjans et al., 2015). Overall, 
the hypothesis that the gut microbiome modulates brain activity through the ‘gut-
microbiota-brain axis’ (Fang, 2015) provides a link between the gut and pathologies 
affecting the brain. In doing so, it opens novel avenues of investigation in the field of the 
gut-brain axis in ALS. 
 
Impaired glucose handling 
Impaired glucose handling and function of insulin is of particular interest in ALS because 
reduced glucose availability could affect overall energy balance and exacerbate neuronal 
dysfunction, particularly in the CNS, which relies predominantly on glucose as fuel. Since 
the 1960s, there have been reports of impaired glucose tolerance and insulin resistance in 
ALS (Cumings, 1962, Ionasescu and Luca, 1964, Steinke and Tyler, 1964, Saffer et al., 
1977, Gotoh et al., 1972, Reyes et al., 1984, Pradat et al., 2010).  
 
A systematic review of seven, predominantly retrospective, observational studies 
found no increase in the prevalence of diabetes mellitus (DM) in ALS (Lekoubou et al., 
2014), although the incidence of abnormal glucose tolerance tests in ALS patients ranges 
from 19% to 72% (Ionasescu and Luca, 1964, Mueller and Quick, 1970, Koerner, 1976, 
Harno et al., 1984, Armon et al., 1991, Pradat et al., 2010). Therefore subtle alterations in 
glucose handling could occur in ALS.  
 
Abnormal glucose metabolism does not appear to affect survival or disease severity 
(Lekoubou et al., 2014, Paganoni et al., 2015); however, one Taiwanese study reported an 
increased risk of ALS in those with DM (Sun et al., 2015). By contrast, a Danish study 
found that type 2 DM is protective for ALS (Kioumourtzoglou et al., 2015) and individuals 
with DM have been found to have a an average of 4 years later onset of ALS than those 
without DM (Jawaid et al., 2010b).  
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While the data examining the relationship between ALS and impaired glucose 
handling is limited and inconclusive, the finding of hyperglycaemia in ALS patients with 
severe muscle wasting (Collis and Engel, 1968, Gotoh et al., 1972, Shimizu et al., 2011) 
raises the possibility that reduced muscle mass may lead to a global disruption in glucose 
homeostasis.  
 
Approximately 90% of insulin-mediated glucose uptake occurs in skeletal muscle 
(Sinacore and Gulve, 1993). Thus, muscle wasting in ALS could affect glucose handling 
by altering insulin-mediated translocation to the muscle membrane of the glucose 
transporter type 4 (GLUT4), which is critical in regulating cellular glucose uptake and 
whole body glucose homeostasis (Henriksen et al., 1991). Congruent with this, muscle 
wasting is correlated with abnormal glucose tolerance in some ALS patients (Collis and 
Engel, 1968, Gotoh et al., 1972), however this correlation is not universal (Mueller and 
Quick, 1970) and controlling for muscle wasting does not affect the occurrence of impaired 
glucose handling (Saffer et al., 1977). Thus, muscle wasting, while a possible contributor, 
is unlikely to be the sole explanation for abnormal glucose handling in all ALS cases.  
 
Animal models of ALS have revealed insights into possible mechanisms of altered 
glucose handling. In the SOD1 mouse, there is impaired glucose use in motor tracts in 
conjunction with significant depletions in cortical ATP (Browne et al., 2006), and 
expression of key enzymes involved in gluconeogenesis (the process of endogenous 
glucose production) are up-regulated in the liver with a concomitant increase in fasting 
glycaemia (Dupuis et al., 2004).  
 
In ALS patients, studies examining insulin and glucose responses using a 
compound that stimulates secretion of insulin, indicate impaired synthesis or release of 
insulin from the pancreas (Saffer et al., 1977, Steinke and Tyler, 1964). Recent findings in 
ALS patients provide further evidence to support an alteration of insulin release and 
function in ALS (Ngo et al., 2015). Reduced circulating levels of gastric inhibitory 
polypeptide in ALS patients (Ngo et al., 2015), could result in insufficient insulin release 
(McIntosh et al., 2009), and reduced expression of circulating pancreatic polypeptide in 
ALS patients (Ngo et al., 2015) could contribute to reduced peripheral insulin action.  
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Mitochondrial dysfunction 
Mitochondria, the main site of oxidative phosphorylation and production of ATP, play a 
pivotal role in bioenergetics and survival of the cell. Mitochondria are also a major source 
of oxygen free radicals and act as regulators of cell death via the intrinsic pathway of 
apoptosis. The nervous system consumes substantial amounts of energy and oxygen, so 
mitochondria are critical to its function [reviewed in (Xavier et al., 2015)]. Mitochondrial 
dysfunction significantly affects neuronal function and survival by increasing neuronal 
sensitivity to a variety of insults such as oxidative stress and bioenergetic defects (Xavier 
et al., 2015). 
 
There is ample evidence that pathological changes in ALS are closely associated 
with changes in mitochondrial morphology and bioenergetics (Hervias et al., 2006, 
Muyderman and Chen, 2014). Such observations have led to the hypothesis that 
mitochondrial dysfunction plays an important role in the pathogenesis of ALS, and a large 
number of studies in ALS patients and animal models have found mitochondrial 
abnormalities in neuronal and non-neuronal tissues [reviewed in (Martin, 2011)].  
 
Animal studies have revealed mitochondrial dysfunction in the pre-symptomatic and 
early phases of disease (Mattiazzi et al., 2002, Damiano et al., 2006, D'Alessandro et al., 
2011, Carri and Cozzolino, 2011, Tan et al., 2014), implying that mitochondrial dysfunction 
is an early event that triggers disease, rather than the end product of neuronal cell 
degeneration.  
 
Mitochondrial dysfunction leads to the accumulation of oxygen free radicals and 
reduced ATP production from oxidative phosphorylation, reducing cell function and energy 
availability, and leading to cell death (Biala et al., 2015, Lionaki et al., 2015). Mitochondrial 
dysfunction in ALS is therefore a potential mechanism of disrupted cellular energy 
production, which could have significant upstream affects on neuronal function and whole 
body energy balance. 
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1.2.3 Attempts to correct metabolic imbalance in ALS 
 
Factors that contribute to energy imbalance in ALS and how these changes could 
exacerbate disease progression have been reviewed above. Strategies and/or drugs to 
improve this energy imbalance could possibly slow disease progression and improve 
survival in ALS and are therefore attractive areas for exploration. A number of therapies 
considering this approach have been hypothesized and tested in ALS (selected strategies 
are illustrated in Figure 1.4).  
 
As discussed above in section 1.2.1, an emerging therapeutic approach in ALS is 
dietary modification and supplementation (Rosenfeld and Ellis, 2008). Improving nutrition 
can improve the outcome in ALS [reviewed in (Ngo et al., 2014)] and provide benefit in 
animal models (Dupuis et al., 2004) and ALS patients (Mazzini et al., 1995, Silva et al., 
2010, Dorst et al., 2013, Wills et al., 2014). For this reason some authors advocate early 
enteral nutrition (Greenwood, 2013).  
 
However, despite the notion that increased calorie intake compensates for 
increased energy demands and improves outcome in ALS, the exact composition of 
dietary intervention, and when to initiate dietary changes, are yet to be determined. This is 
particularly important as significant weight gain in some ALS patients may impair 
respiratory muscle function and mobilization (Héritier et al., 2015). The best method for 
monitoring the response to nutritional interventions has yet to be determined, and it is 
currently unknown whether anthropometric predictors of FM are accurate in ALS and can 
be used to guide nutritional advice. 
 
Other dietary modifications that aim to alter energy substrate supply and/or promote 
anaplerosis (replenishing depleted metabolic intermediates), including the ketogenic diet 
(Zhao et al., 2006), the "Deanna protocol" (Fournier et al., 2013, Ari et al., 2014) and 
triheptanoin (Tefera et al., 2016), could potentially be useful in treating the energy deficit in 
ALS, but need further formal testing.  
 
 43 
Drug therapies that improve metabolic imbalance could improve outcome in ALS, 
but this is a largely unexplored area. It is postulated that agents that stimulate glucose 
transport (such as glycogen synthase kinase-3 inhibitors) and block hyperexcitability 
(including retigabine, flecainide and diazoxide), as well as mitoprotective drugs (agents 
that preserve mitochondrial function), could be beneficial (Table 1.2). 
 
Given the link between ALS and glucose intolerance, therapies that improve insulin 
resistance in type 2 diabetes have been explored in ALS. The anti-diabetic drug 
pioglitazone improved motor performance, delayed weight loss, attenuated motor neuron 
loss, and extended survival in a SOD1 mouse model (Kiaei et al., 2005), however, 
pioglitazone failed to show efficacy in a phase II clinical trial of ALS patients (Dupuis et al., 
2012). Furthermore, it has been suggested that anti-diabetic drugs are detrimental in ALS 
in light of emerging evidence that some features of the metabolic syndrome may be 
protective in ALS (Jawaid et al., 2014). Since the trial of pioglitazone, no further diabetic 
agents have been studied in ALS and therefore the uncertainty of benefit from anti-diabetic 
drugs remains.  
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Figure 1.4 Proposed treatment strategies aimed at restoring metabolic homeostasis 
to slow disease progression in ALS. This shows strategies that could potentially correct 
or compensate for the energy deficit in ALS patients. Enteral nutrition is generally 
accepted to be a safe strategy to maintain body weight in ALS (Wills et al., 2014). 
However, further studies to determine the optimal diet composition and the ideal time to 
initiate enteral feeding are required. Non-invasive ventilation has been shown to improve 
quality of life and survival in ALS (Bourke et al., 2003). The other strategies in the figure 
are proposed based on their theoretical plausibility; however they require further validation 
to determine safety and efficacy in ALS. More information on these experimental 
strategies is included in Table 1.2. Abbreviations: CNS, central nervous system; GSK-3, 
glycogen synthase kinase-3. 
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Table 1.2 Tested strategies that could improve metabolic imbalance in ALS 
Strategy 
Potential mechanism 
to improve metabolic 
imbalance in ALS 
Summary of evidence in ALS or 
models of ALS 
Possible future 
directions 
Increase calorie 
intake through 
dietary 
supplementation 
and enteral 
nutrition 
• Maintains energy 
stores and 
compensates for 
increased energy 
demands  
• Provides energy 
substrate for 
lipolysis, which is 
increased in ALS 
Patient data 
• High caloric food supplements 
stabilized body weight in ALS 
patients (Dorst et al., 2013) 
• Oral supplementation increased 
BMI in ALS patients (Silva et al., 
2010) 
• PEG feeding maintained BMI and 
reduced mortality in bulbar onset 
ALS (Mazzini et al., 1995)  
• Hypercaloric nutrition with ‘Jevity’ 
(contains 29% of calories from 
fat) via PEG was safe and 
tolerable in ALS patients (Wills et 
al., 2014)  
• High caloric intake (1,500 
kcal/day) via PEG prolonged 
survival (Dorst et al., 2015) 
• Trials currently recruiting: ‘Oral 
Nutritional Supplementation in 
ALS Patients’ (ClincalTrials.gov) 
and ‘Efficacy, Safety and 
Tolerability of High Lipid and 
Calorie Supplementation in ALS’ 
(ClinicalTrials.gov) 
 
Animal studies 
• High calorie diet extended mean 
survival by 20% in SOD1 mice 
(Dupuis et al., 2004) 
 
• Determine the 
optimal 
composition of 
diet and calorie 
content to 
maintain weight in 
ALS 
• Longitudinal 
studies that 
examine disease 
progression 
relative to dietary 
intake and 
metabolic 
parameters 
• Develop 
consensus 
guidelines on 
initiating enteral 
feeding 
Boost the 
supply of 
alternate energy 
substrates 
including ketone 
bodies, 
intermediates in 
the TCA cycle 
and medium 
chain fatty acids  
• Ketones are an 
alternate energy 
substrate for 
neurones  
• Energy deficit might 
be improved by 
providing alternative 
substrate (acetyl-
CoA) for the TCA 
cycle and the ETC 
for enhanced ATP 
production 
• Beneficial in other 
disorders of altered 
neuronal 
metabolism 
(Baranano and 
Hartman, 2008) 
Patient data 
• ‘Safety and Tolerability of the KD 
in ALS Trial’ (ClinicalTrials.gov) 
terminated May 2015, results not 
published 
 
Animal studies 
• KD maintained motor function 
and reduced spinal cord motor 
neuron death in SOD1 mice 
(Zhao et al., 2006)   
• DP improved motor scores and 
improved survival in SOD1 mice 
(Ari et al., 2014) 
• Caprylic triglyceride attenuated 
progression and protected spinal 
cord motor neuron loss in SOD1 
mice (Zhao et al., 2012) 
• Studies in ALS 
models to 
elucidate 
mechanisms  
• Trials in ALS 
patients to 
determine safety 
and efficacy  
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Inhibit GSK-3 • GSK-3 has been 
proposed to play a 
role in the 
pathogenesis of 
ALS (Grimes and 
Jope, 2001) 
• Blocking the action 
of GSK-3 enhances 
glycogen synthesis 
and stimulates 
glucose transport in 
skeletal muscle 
(Jope and Johnson, 
2004), which might 
enhance energy 
utilization in skeletal 
muscle 
 
Animal studies 
• Administration of a GSK-3 
inhibitor delayed the onset of 
symptoms and prolonged survival 
in SOD1 mice (Koh et al., 2007) 
 
In vitro studies 
• Increased GSK-3 activity found in 
motor neuronal model of ALS; 
GSK-3 inhibition prevented motor 
neurone cell death (Koh et al., 
2005) 
 
• Studies in ALS 
models to 
elucidate 
mechanisms. 
• Trials in ALS 
patients to 
determine safety 
and efficacy. 
Improve 
mitochondrial 
function  
 
• Agents that improve 
mitochondrial 
function might 
reduce oxidative 
stress and optimize 
mitochondrial 
electron transport 
and ATP synthesis. 
Patient data 
• Phase III trial of dexpramipexole 
(Mora et al., 2013), phase II trial 
of Coenzyme Q10 (Kaufmann et 
al., 2009) and a pilot study of 
tauroursodeoxycholic acid (Elia et 
al., 2016) showed no benefit 
• A phase I study of BIIB067 is 
currently underway 
(ClincalTrials.gov) 
Animal studies 
• Dichloroacetate improved 
functional status of mitochondria 
and increased survival in SOD1 
mice (Miquel et al., 2012) 
• Delta9-THC prolonged survival in 
SOD1 mice possibly via reducing 
oxidative cell damage (Raman et 
al., 2004) however side effects 
are likely to be dose-limiting in 
patients (Joerger et al., 2012) 
• TRO19622 extended survival in 
SOD1 mice (Bordet et al., 2007) 
• Arimoclomol delayed progression 
(Kieran et al., 2004) and 
extended survival (Kalmar et al., 
2008) in SOD1 mice  
• Valproate improved oxidative 
stress in SOD1 mice (Rouaux et 
al., 2007) 
In vitro studies 
• Methyl pyruvate treatment 
improved mitochondrial ATP 
production in a SIGMAR1 model 
of ALS (Tagashira et al., 2014).   
• SS-31 improved mitochondrial 
electron transport and ATP 
synthesis (Birk et al., 2014) 
 
 
• Studies in ALS 
models to 
elucidate 
mechanisms  
• Larger studies in 
ALS patients of 
agents that show 
benefit in animal 
models 
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Abbreviations: ALS, Amyotrophic lateral sclerosis; BMI, body mass index; DP, Deanna protocol; ETC, 
electron transport chain; GSK-3, glycogen synthase kinase-3; kcal/day, kilocalories per day; KD, ketogenic 
diet; PEG, percutaneous endoscopic gastrostomy; TCA, tricarboxylic acid cycle; THC, tetrahydrocannabinol. 
 
Block neuronal 
hyperexcitability  
• Blocking neuronal 
hyperexcitability 
could correct 
neuronal energy 
imbalance by 
reducing excessive 
energy use 
Patient data 
• Phase II trial of talampanel 
(Pascuzzi et al., 2010) and a 
Phase II/III trial of memantine (de 
Carvalho et al., 2010) showed no 
significant benefit   
• Phase II trial of retigabine on 
neuronal excitability in ALS 
currently underway 
(ClincalTrials.gov) 
• A pilot study found that flecainide 
stabilized axonal membrane 
function. Not powered to detect 
benefit (Park et al., 2015a) 
Animal studies 
• Diazoxide improved survival in 
SOD1 mice (Pugliese et al., 
2013) 
 
In Vitro studies 
• Retigabine blocked neuronal 
hyperexcitability and improved 
motor neurone survival (Wainger 
et al., 2014) 
 
 
• Studies in ALS 
models to 
elucidate 
mechanisms 
• Larger studies in 
ALS patients of 
agents that show 
benefit in animal 
models 
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1.3 Summary of metabolism in ALS and rationale for the thesis 
 
The death of motor neurones in ALS is likely to occur secondary to a combination of 
genetic susceptibility and environmental factors. However, the considerable heterogeneity 
in the clinical features of ALS and the different clinical courses seen in patients with the 
same pathogenic mutation indicate that other factors modify the disease. There is 
evidence that altered energy metabolism occurs in ALS and that the resulting energy 
imbalance could modify disease progression.  
 
Fat mass in ALS 
Of clinical significance, FM and nutritional status modify survival in ALS (Mazzini et al., 
1995, Stambler et al., 1998, Dupuis et al., 2004, Silva et al., 2010, Paganoni et al., 2011, 
Shimizu et al., 2012, Dorst et al., 2013, Wills et al., 2014). The assessment of FM can be 
used to guide nutritional management, which is emerging as an important aspect of 
routine care in ALS patients. Although anthropometric measurements are widely used in 
clinical practice to estimate FM, it is currently unknown whether they are accurate 
predictors of FM in ALS patients.   
 
Anthropometric measurements, including BMI (Eknoyan, 2008) and BAI (Bergman et 
al., 2011), are commonly used to predict adiposity in clinical and research settings. 
Anthropometric measurements could be convenient predictors of FM in ALS patients, 
particularly in those who have significant physical disability or respiratory impairment, 
which could preclude the use of other measures of FM, such as dual-energy x-ray 
absorptiometry (DEXA) or magnetic imaging resonance (MRI) (discussed in Chapter 2, 
section 2.1). Furthermore, as the monitoring of responses to nutritional intervention 
requires longitudinal assessment of FM, the rapid and practical nature of anthropometric 
measures makes them convenient for repeated use in a clinical setting.  
 
Despite the high practicality of using anthropometric measures in ALS, their 
accuracy in this patient group is currently unknown. BMI (Norgan, 1994, Garrido-Chamorro 
et al., 2009) and BAI (Johnson et al., 2012) have been shown to be inaccurate predictors 
of FM in populations with altered muscle mass. Therefore, it is plausible that the alteration 
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in body composition that occurs in ALS (Nau et al., 1995, Kasarskis et al., 1996, Desport 
et al., 1999, Desport et al., 2000, Jawaid et al., 2010a) could reduce the predictive 
accuracy of anthropometric measurements.  
 
Given the importance of accurately assessing FM for optimal nutritional care, 
inaccurate or misleading estimates of adiposity could have adverse clinical consequences. 
It is therefore of clinical interest to assess whether BMI and BAI are accurate estimates of 
FM in ALS patients.  
 
 
Hypermetabolism in ALS 
There have been studies demonstrating hypermetabolism in some patients with ALS 
(Kasarskis et al., 1996, Desport et al., 2001, Desport et al., 2005, Bouteloup et al., 2009, 
Funalot et al., 2009, Kasarskis et al., 2014), however, the cause of hypermetabolism is 
unknown. The few studies that have assessed clinical correlates of hypermetabolism do 
not identify its underlying mechanisms (Kasarskis et al., 1996, Desport et al., 2001, 
Desport et al., 2005, Bouteloup et al., 2009). 
 
Given than hypermetabolism has been observed in relation to proximity to death in 
ALS patients (Kasarskis et al., 1996), metabolic abnormalities are hypothesized to be 
associated with a poor disease outcome in ALS. This is of interest because if this is a 
casual relationship, then strategies to correct or compensate for increased energy 
requirements could be used to modify disease course. For example, improved nutrition, 
which could potentially compensate for the higher energy needs associated with 
hypermetabolism, has been shown to reduce mortality in ALS patients (Mazzini et al., 
1995, Wills et al., 2014, Dorst et al., 2015). 
 
Importantly, previous studies of hypermetabolism in ALS have limitations and modified 
approaches could be explored. Existing studies have not accounted for the alteration in 
body composition that occurs in ALS (Kasarskis et al., 1996, Desport et al., 2001, Desport 
et al., 2005, Bouteloup et al., 2009, Funalot et al., 2009, Kasarskis et al., 2014). This could 
be important, as body composition is the greatest determinant of REE (Johnstone et al., 
2005). It is currently unknown how accounting for body composition affects predictions of 
REE in ALS. Also previous studies have assessed ALS patients with advanced disease 
 50 
without matched controls. Therefore, studies of ALS patients earlier in their disease course 
and assessed in comparison to matched controls are currently lacking.  
 
Metabolic abnormalities that are found in ALS patients suggest possible mechanisms 
through which disease could be modified. Strategies to correct or compensate for energy 
imbalance in ALS could benefit neuronal survival, and are therefore promising avenues to 
improve quality of life and survival in patients living with ALS. However, before progress 
can be made, further knowledge on the incidence, clinical correlations and consequences 
of metabolic dysfunction must be established.  
 
1.4 Objectives of the Thesis 
 
1) To determine whether the commonly used anthropometric measurements BMI and BAI 
are accurate predictors of FM in ALS patients compared to age- and sex-matched 
controls.  
 
2) To study hypermetabolism in ALS patients and age- and sex- matched controls by: 
a) Investigating the incidence of hypermetabolism using an REE prediction model that 
accounts for body composition.  
b) Investigating clinical factors that are associated with hypermetabolism in ALS 
patients.  
c) Determining whether hypermetabolism affects disease progression in ALS patients 
by measuring changes in the ALSFRS-R score over a 4-month period. 
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Chapter 2: Body composition and resting energy expenditure 
(REE): Background and assessment 
 
 
Reduced body energy stores in the form of fat mass (FM) (Nau et al., 1995, Kasarskis et 
al., 1996, Desport et al., 1999, Desport et al., 2000, Jawaid et al., 2010a) and increased 
resting energy expenditure (REE) (Kasarskis et al., 1996, Desport et al., 2001, Desport et 
al., 2005, Bouteloup et al., 2009, Funalot et al., 2009, Kasarskis et al., 2014) are key 
clinical features of the metabolic disturbance that has been reported in some ALS patients. 
These aspects of metabolism will be investigated in the thesis. In order to develop the 
methodology and to provide scientific context, this chapter discusses the general 
background of body composition and REE including a review of common methods for their 
assessment. 
 
2.1 Body composition 
 
An interest in the relationship between nutrition, altered body composition and disease 
dates back to the time of Hippocrates (Cardenas, 2013). Today, knowledge of body 
composition is fundamental to the study of human physiology, metabolism and nutrition 
(Kondrup et al., 2003, Kyle et al., 2006).  
 
Body composition refers to the relative components of the total body mass. Body 
composition can be conceptualized in five compartments; atomic, molecular, cellular, 
tissue or whole body compartments (Wang et al., 1992). For the clinical and nutritional 
purposes relevant to this thesis, body composition will be considered in a two-
compartment model. This model partitions the body into FM and fat free mass (FFM) 
(Forbes, 1999). FFM comprises the metabolically active body components including 
muscle, internal organs, bone and connective tissue. Many techniques exist to investigate 
body composition. Commonly used techniques are discussed in the following sections and 
the advantages and disadvantages are summarized in Table 2.1. 
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Table 2.1 Commonly used techniques to assess body composition. Advantages and 
disadvantages are discussed in general and in relation to ALS patients, particularly those 
with respiratory dysfunction who are unable to lie flat.  
Technique Advantages Disadvantages 
 Anthropometric 
measurements (for 
example BMI 
(Eknoyan, 2008) and 
BAI (Bergman et al., 
2011) 
Rapid, simple, portable 
comfortable, inexpensive, safe.  
Do not require specialized 
equipment or training. Practical 
and efficient. 
Population specific, poor 
accuracy in individuals with 
altered fat free mass as is 
commonly the case in ALS  
Air displacement 
plethysmography  
Rapid, comfortable, and safe. 
Automated and non-invasive. 
Practical and efficient.  
Expensive equipment. Not 
portable. Not suitable for 
individuals with claustrophobia. 
May be inaccurate in individuals 
with fluid shifts (such as oedema, 
ascites or dehydration) or 
extremely altered body 
composition. 
 
Dual-energy x-ray 
absorptiometry  
Accurate. Exposure to ionizing radiation. 
Not portable. Expensive 
equipment and technical staff. 
Requires highly skilled 
interpretation. Not practical in 
ALS patients with respiratory 
dysfunction as requires lying 
supine for long periods. 
Magnetic resonance 
imaging 
Accurate. Provides an estimate 
of regional body composition. 
Expensive equipment and 
technical staff. Requires highly 
skilled interpretation. Only 
quantifies FM that is present in 
adipose tissue (does not quantify 
total FM). Not practical in ALS 
patients with respiratory 
dysfunction as requires lying 
supine for long periods. 
Abbreviations: BMI, body mass index; BAI, body adiposity index; ALS, amyotrophic lateral 
sclerosis; FM fat mass. 
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2.1.1 Anthropometric measures 
 
Anthropometric measurements, including body mass index (BMI) and body adiposity index 
(BAI) are commonly employed methods of assessing body composition in clinical and 
research practice. They are accessible, quick and efficient ways to estimate FM. However, 
they are in fact ‘predictors’ of body composition, as they do not directly measure body 
composition. Anthropometric measurements are derived from mathematical models that 
take into account demographic indices and raw measurements of physical properties of 
the body, primarily dimensions of body size and shape, and apply various theoretical 
assumptions (Wells and Fewtrell, 2006).  
 
Due to these assumptions, the accuracy of anthropometric measures is population 
dependent. For example, BAI is not an accurate predictor of FM in individuals with 
extreme levels of adiposity (Bergman et al., 2011) and it lacks accuracy in obese 
individuals (Geliebter et al., 2013) and healthy sedentary females (Suchanek et al., 2012). 
Anthropometric measures can also overestimate FM in individuals with significantly 
increased FFM such as body builders (Madden and Smith, 2016). The validity of 
anthropometric measures in individuals with reduced FFM, such as ALS patients, is 
currently unknown.  
 
2.1.2 Air displacement plethysmography 
 
Whole body air-displacement plethysmography (ADP) has been used to measure body 
composition for over a century, but only became available for routine use after the 
development of an automated system called the BodPod (Cosmed USA, Inc), in the mid-
1990s (Dempster and Aitkens, 1995).  
 
Plethysmography refers to the measurement of size, and in the case of ADP refers 
to the measurement of body volume.  In ADP, the volume of a subject is measured 
indirectly by measuring the volume of air displaced inside an enclosed chamber, known as 
a plethysmograph. The BodPod system is comprised of a plethysmograph, electronic 
weighing scale, computer, software and, calibration weights and cylinder. 
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The BodPod has been found to be a reliable, reproducible and valid method for 
determining body composition (Fields et al., 2002, Noreen and Lemon, 2006, Anderson, 
2007, Lee and Gallagher, 2008, Lowry and Tomiyama, 2015). It offers a rapid and 
automated evaluation of body composition. It avoids exposure to ionizing radiation and is 
practical for subjects who are otherwise challenging to assess, including the elderly, 
children, and individuals with physical disabilities. However, in some populations, including 
individuals with fluid shifts and/or extremely altered body composition, there could be 
inaccuracies in the measurement of body composition due to the assumptions inherent to 
the two-compartment model of densitometry used by the BodPod (Fields et al., 2002). 
 
2.1.3 Dual-energy x-ray absorptiometry  
 
Dual-energy x-ray absorptiometry (DEXA) was originally developed to measure bone 
mineral density, which is calculated from the differential absorption of x-rays of two 
different energies (Pietrobelli et al., 1996). This calculation requires quantification of 
overlying soft tissue, therefore values of FM and FFM are also obtained during a DEXA 
scan. 
  
DEXA is widely used for the purposes of evaluating bone health, however, the 
equipment and technical staff required are expensive, the scan exposes the subject to 
ionizing radiation and the images require highly specialized interpretation. Regarding its 
use for assessment of body composition, although able to accurately quantify whole body 
FM (Toombs et al., 2012), DEXA could be unreliable for longitudinal studies of individuals 
who undergo significant changes in nutritional status between measurements with bias 
present in some disease states (Williams et al., 2006). 
 
2.1.4 Magnetic resonance imaging 
 
Magnetic resonance imaging (MRI) is based on intrinsic tissue properties. MRI analyzes 
the absorption and emission of radio frequency energy, and generates images based on 
variations in the phase and frequency of the absorbed and emitted energy (de Figueiredo 
et al., 2011). MRI uses a multi-compartmental model to assess soft tissue, bone, organ 
size, muscle, fat distribution and total body water. It allows for accurate quantification of 
adipose tissue, skeletal muscle and organs.  
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The main advantage of MRI is its ability to estimate regional body composition 
(Müller et al., 2011). However, given the molecular basis of MRI, comparing measures 
from other techniques can be difficult. MRI makes assumptions regarding the fat content of 
adipose tissue and the density of fat, and MRI can only quantify fat that is present in 
adipose tissue (Wells and Fewtrell, 2006), rather than total FM which is measured by 
densitometry models. MRI is expensive and, requires specialized technical staff and highly 
skilled interpretation. The imaging acquisition is relatively slow, therefore subjects are 
required to lie supine inside a ‘donut’ shaped magnet for long periods of time. This can be 
unsuitable for individuals with claustrophobia and mental or physical disability. These 
disadvantages limit the use of MRI in routine metabolic assessments. 
 
2.1.5 Summary  
 
Assessment of body composition provides important information in the study of 
metabolism and nutrition. Although many methods exist for  predicting and assessing body 
composition, as pathologist Beneke remarked in 1878, 'Nothing is measured with greater 
error than the human body'. Overall, no method for assessment of body composition has 
been shown to be ideal in all populations. The technique of choice depends upon the 
characteristics of the test subject and available resources. The limitations of each method 
should be acknowledged in the context of the population being studied.  
 
2.2 Resting energy expenditure 
 
Total daily energy expenditure (TDEE) is a composite of resting energy expenditure 
(REE), activity-dependent energy expenditure, and the thermogenic effect of food [TEF, 
the energy required to digest, process and absorb nutrients (D'Alessio et al., 1988)]. REE 
reflects the energy required for vital functions of respiration, cardiac output and 
maintenance of intra-cellular environments, in a fasted state. In healthy adults REE 
accounts for up to 75% of overall energy expenditure (Donahoo et al., 2004) (figure 2.1).  
 
 
 
 
 56 
 
 
Figure 2.1 Components of total daily energy expenditure. Abbreviations: REE, resting 
energy expenditure; TEF, thermic effect of food; Activity, activity dependent energy 
expenditure. Proportions from Donahoo et al (Donahoo et al., 2004). 
 
 
 
REE is predominantly dependent on body composition (Johnstone et al., 2005) and 
correlates with FFM and FM in both women and men (Nielsen et al., 2000). A study in 
elderly individuals found that approximately 88% of the variance in REE is explained by 
changes in mass and body composition (Geisler and Müller, 2017). The greatest 
determinant of REE is FFM (Wang et al., 2000, Johnstone et al., 2005), the metabolically 
active component of the body comprised of internal muscle, organs, bone, water and 
connective tissue. REE is also linked to appetite control (Blundell et al., 2012) and adjusts 
in response to central nervous system pathways that regulate energy homeostasis 
(Keesey and Powley, 2008).  
 
REE varies significantly relative to age, sex, body composition and general health 
(Johnstone et al., 2005, Geisler et al., 2016). REE displays a diurnal variation (Fredrix et 
al., 1990) and can be increased by the consumption of stimulants including caffeine 
(Astrup et al., 1990) and nicotine (Audrain-McGovern and Benowitz, 2011).  
 
 
REE  
TEF
Activity
~75%
~15%
~10%
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2.2.1 Predictions of REE 
  
When REE cannot be directly measured, predicted REE (pREE) is used across many 
clinical disciplines to inform nutritional requirements. In particular, pREE is commonly used 
to guide total parenteral nutrition during critical illness (Plank and Hill, 2003). Another 
important function of the pREE is its use as a comparison value to the measured REE 
(mREE), in order to determine whether an individual’s mREE is abnormal.  
 
There are numerous models for determining pREE that take into account various 
demographic, anthropometric and/or body composition measures (Frankenfield et al., 
2005, Wang et al., 2001). 3 commonly used models are compared in Table 2.2A and B.  
 
Table 2.2A Resting energy expenditure prediction models.  
Prediction 
model for REE 
(kcal/day) 
Equation 
Harris-Benedict 
(Harris and 
Benedict, 1918) 
Males: 66.4730 + 13.7516 wt (kg) + 5.0033 ht (cm) - 6.7550 age (yrs) 
Females: 655.0955 + 9.5634 wt (kg) + 1.8496 ht (cm) - 4.6756 x age 
(yrs) 
Mifflin-St Jeor 
(Mifflin et al., 
1990) 
Males: 10 x wt (kg) + 6.25 x ht (cm) – 5.0 x age (yrs) +5  
Females: 10 x wt (kg) + 6.25 x ht (cm) – 5.0 x age (yrs) – 161                                                                                           
Modified 
Nelson*(Nelson 
et al., 1992). 
25.80 x FFM (kg) + 4.04 x FM (kg)  
Notes: *The originally described Nelson equation (Nelson et al., 1992) calculated the 
pREE in kilojoules/day (kJ/day), the version shown in the table is the modified version 
used by the BodPod body composition measuring system (Cosmed USA, Inc) to calculate 
the pREE in kilocalories/day (kcal/day). This adaptation can be found at: 
http://www.bodpod.com/hires/marketing_literature/product_news/Product_News_Estimatio
n_of_RMR_based_on_Lean_Mass_with_Bod_Pod_EN_print.pdf 
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Table 2.2B Comparison of parameters considered in three commonly used pREE 
models. Abbreviations: Kcal/day, kilocalories per day; REE, resting energy expenditure. 
Prediction 
model for REE 
(kcal/day) 
Considers 
weight 
Considers 
height 
Considers 
age 
Considers 
sex 
Considers 
body 
composition 
Harris-Benedict  ✓ ✓ ✓ ✓ x 
Mifflin-St Jeor ✓ ✓ ✓ ✓ x 
Nelson  x x x x ✓ 
Abbreviations: REE, resting energy expenditure; wt, weight; ht, height; FFM, fat free mass; 
FM, fat mass; yrs, years. 
 
The American Dietetic Society suggests use of the Miflin-St Jeor equation (Mifflin et 
al., 1990). The Harris-Benedict equation (Harris and Benedict, 1918) is also widely used, 
particularly in studies of ALS patients as discussed in Chapter 1 section 1.2.2 (Kasarskis 
et al., 1996, Desport et al., 2001, Desport et al., 2005, Bouteloup et al., 2009, Funalot et 
al., 2009, Kasarskis et al., 2014).   
 
While the Mifflin-St Jeor and Harris-Benedict equations are commonly used to 
predict REE (Ellis and Rosenfeld, 2011), these predictions do not account for body 
composition. Given that body composition, and in particular, FFM (Johnstone et al., 2005), 
is the major determinant of REE, these equations are inherently inaccurate in individuals 
with altered body composition (Weijs et al., 2008), for example ALS patients (Sherman et 
al., 2004, Siirala et al., 2010).  
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Studies have shown that REE prediction equations differ significantly (Miller et al., 
2013, Flack et al., 2016) and that the Harris-Benedict equation could overestimate REE 
when compared to indirect calorimetry (Kisiolek et al., 2015). A study of women in different 
age groups suggests that the Nelson prediction, which accounts for body composition, is 
accurate in older individuals (Woolf, 2015). This is most likely because it accounts for the 
amounts of FM and FFM, which are altered in the elderly (St-Onge and Gallagher, 2010, 
Geisler et al., 2016). Given the important influence that body composition has on REE, it 
has been suggested that accounting for body composition is critical in predicting REE 
(Wang et al., 2000).  
 
Overall, REE prediction models rely on various assumptions and are therefore 
associated with inherent errors. The evidence suggests that caution should be exercised 
when choosing a pREE model, and that specific population characteristics, such as age, 
sex and most importantly body composition, should be taken into account where possible. 
 
2.2.2 Abnormalities of REE 
 
A significant difference between mREE and the pREE reflects an underlying 
physiological disturbance and a change in energy requirements. This is most often 
associated with systemic illness. A decrease in the mREE relative to the pREE is known 
as a hypometabolic state. Hypometabolism is known to occur in association with 
hypothermia (Gordon, 2001) and endocrine disorders including hypothyroidism (Persani, 
2012). 
 
Conversely, an increase in REE relative to the pREE is known as a hypermetabolic 
state. Clinical conditions characteristically associated with hypermetabolism include 
hyperthyroidism (Roth and McAuliffe, 1989), pheochromocytoma (McCullagh and Engel, 
1942), malignancy (Purcell et al., 2016), burns (Auger et al., 2017) and significant trauma 
(Rogobete et al., 2017). Given reports of hypermetabolism in ALS, the clinical 
consequences and possible mechanisms of hypermetabolism in other disorders will be 
considered.  
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2.2.3 Clinical consequences of hypermetabolism 
 
Hypermetabolism is associated with a negative nitrogen balance, cachexia, insulin 
resistance and increased catabolism of protein, carbohydrates and triglycerides 
(Challoner, 1966, Nair et al., 1984, Nair et al., 1986, Bogardus et al., 1986, Chiolero et al., 
1997, Charlton and Nair, 1998, Sreekumar and Nair, 2007). In severe burns, 
hypermetabolism is associated with significant catabolism of skeletal muscle (Newsome et 
al., 1973, Hart et al., 2000) and, diminished mitochondrial coupling in skeletal muscle 
(Porter et al., 2016) and brown adipose tissue (Yo et al., 2013). In extreme cases, 
hypermetabolism can be life threatening and require critical care (Wu et al., 2015a). 
 
Much of the research on the consequences of hypermetabolism has been carried 
out in cancer and burns patients or in an intensive care unit (ICU) setting. It has recently 
been shown that hypermetabolism correlates with clinical and biological markers of cancer 
cachexia and is associated with a shorter survival in metastatic cancer patients (Vazeille et 
al., 2017). Hypermetabolism in patients with severe sepsis in ICU predicts a worse 
mortality (Wu et al., 2015a). Similarly hypermetabolism following severe burns is 
associated with increased cardiac workload, muscle wasting and increased morbidity 
(Herndon  et al., 2001).  
 
From a therapeutic aspect, it has been shown that effective modulation of 
hypermetabolism in burns patients (via beta-adrenergic blockade and reduction of 
endogenous catecholamine actions) reduces inflammation, and improves biochemical and 
clinical outcomes (Herndon  et al., 2001, Lunawat et al., 2015). Given that 
hypermetabolism has also been speculated to lead to a worse outcome in ALS patients, 
these observations that modulation of hypermetabolism improves outcomes in burns 
patients, raise the possibility that metabolic therapies could also be beneficial in ALS. 
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2.2.4 Possible mechanisms of hypermetabolism 
 
Hypermetabolism occurs across a spectrum of clinical conditions and a number of different 
mechanisms are thought to contribute to its development.  
 
In thyrotoxicosis, hypermetabolism arises from the direct effects of thyroid hormone, 
which has widespread actions in the hypothalamus, adipose tissue and skeletal muscle, 
and plays a central role in regulating metabolic rate, thermogenesis and glucose 
metabolism (Mullur et al., 2014). Endogenous catecholamines, which increase adrenergic 
stress, are thought to be the primary mediators of hypermetabolism in pheochromocytoma 
(McCullagh and Engel, 1942), trauma and burns (Reiss et al., 1956, Wilmore et al., 1974, 
Porter et al., 2014).  
 
Systemic inflammation and increased metabolism in cancerous and adipose tissue 
have been proposed to lead to hypermetabolism in cancer patients (Petruzzelli and 
Wagner, 2016). In critically ill patients, a combination of a systemic inflammatory response, 
oxidative stress and mitochondrial dysfunction have been suggested to contribute to the 
development of hypermetabolism (Rogobete et al., 2017). It is possible that a combination 
of overlapping mechanisms lead to hypermetabolism in different clinical contexts. 
 
 
2.2.5 Clinical assessment of REE 
 
All energy production in the body occurs from metabolism of ingested nutrients. The final 
common pathway of extracting the chemical energy of cellular fuels (also known as energy 
substrates, including carbohydrate, fat, and protein) is oxidization to carbon dioxide and 
water. Heat is also generated in the processes of substrate combustion.  
 
Direct calorimetry measures total heat loss by evaporation, radiation, and 
conduction/convection from the body (Webb, 1980). To undergo direct calorimetry, the test 
subject must be confined in a thermally isolated chamber to measure heat production 
whilst maintaining a resting state (Webb, 1980). Direct calorimetry is time consuming, 
requires expensive equipment and the conditions are not practical for clinical use. The 
availability of direct calorimetry is limited to a few specialized research centers and since 
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the early 1900’s it has been largely superseded by indirect calorimetry (Ferrannini, 1988, 
Simonson and DeFronzo, 1990, Battley, 1995, da Rocha et al., 2006, Haugen et al., 2007, 
Oshima et al., 2016). 
 
Indirect calorimetry measures whole body oxygen consumption (VO2) and carbon 
dioxide production (VCO2) to estimate the total energy production (Ferrannini, 1988). 
“Energy production” refers to the conversion of substrates into the chemical energy of ATP 
plus loss of some energy during the oxidation process. Given that energy production and 
expenditure are equal in the steady state, i.e., at rest with no change in body temperature, 
the rate of energy production is an accurate estimate of energy expenditure (Ferrannini, 
1988). Indirect calorimetry uses stoichiometry models of substrate oxidative reactions and 
applies the assumptions that all the O2 consumed has been used to oxidize degradable 
fuels, and that all the CO2 that is produced is measured by the system.  
 
Measures of VO2 and VCO2 can be transformed into energy expenditure in 
kilocalories per day (kcal/day), with a correction for the metabolism of protein, by applying 
the widely used Weir equation (Weir, 1949). This equation is derived from first principles 
for the calorie value of a litre of oxygen metabolizing a mixture of carbohydrate, protein 
and fat (Weir, 1949): 
   
Weir equation: EE (kcal/day) = [ (3.941 x VO2) + (1.11 x VCO2) - (2.17 x uN2) ] x 1440 
Where EE is energy expenditure (kcal/day), VO2 is O2 consumption, VCO2 is CO2 
production (L/min) and uN2 is urinary nitrogen (g/day). The factor of 1440 allows for the 
calculation of EE in kcal/day. 
 
Given that in the original publication, Weir et al stated that the error in neglecting 
the effects of protein metabolism is low  (~1% for each 12.3% of total calories arising from 
protein) (Weir, 1949), the Weir equation is often abbreviated to omit accounting for urinary 
nitrogen, which reflects protein metabolism. This abbreviated equation is used by most 
modern indirect calorimetry systems (Blond et al.). 
 Abbreviated Weir equation:  EE (kcal/day) = [ (3.94 X VO2) + (1.11 X VCO2) ] x 1440 
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2.2.6 Summary 
 
Alterations in REE reflect a change in whole body energy metabolism, which is often 
associated with significant systemic illness. The interpretation of alterations in REE is 
complex because it requires consideration of an expected or ‘predicted’ REE (pREE), 
which has inherent limitations. Given that body composition is the greatest determinant of 
REE, pREE models that account for FM and FFM appear to be the most accurate, 
particularly in populations with altered body composition. Hypermetabolism has been 
shown to be detrimental to outcomes in some populations and modification of the 
underlying mechanisms of hypermetabolism could be a potential therapeutic tool. Indirect 
calorimetry is widely considered to be the method of choice for measuring REE in most 
clinical and research settings. 
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Chapter 3:  Methodology 
 
3.1 Participants  
3.1.1 Recruitment  
 
ALS patients 
Patients who attended the Royal Brisbane and Women’s Hospital (RBWH) motor neurone 
disease (MND) clinic were given information by their treating neurologist regarding the 
research and asked if they were provisionally interested in participating. Patients who 
expressed an interest were then invited to attend the RBWH MND research clinic on a 
separate occasion. At the research clinic, the investigator provided further detailed 
information regarding all aspects of the research assessment. ALS patients were enrolled 
if they fulfilled the following inclusion criteria:  
 
1) Fulfillment of the revised El Escorial criteria for probable or definite ALS (Brooks et 
al., 2000, Ludolph et al., 2015) 
2) Fulfillment of the 2008 consensus electrodiagnostic criteria for ALS (de Carvalho et 
al., 2008). 
3) Aged over 18 years 
4) Willing and able to provide informed consent 
 
Patients who had any of these exclusion criteria were not recruited: 
 
1) Respiratory failure or cognitive impairment to a degree that would detrimentally 
affect participation in research assessments 
2) Concomitant conditions or medications known to affect the parameters of interest 
(mainly diabetes, cancer, thyroid dysfunction, active inflammatory or infective 
conditions. However, those with other well-controlled chronic diseases such as 
hypertension and stable heart disease were not excluded).  
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Healthy control participants 
 Healthy control participants were recruited from individuals who presented to the research 
clinic with patients or other contacts of ALS patients (for example spouses, friends, 
colleagues or family members). Where possible the control participants were age- and 
sex-matched to the ALS patients. All controls met the following inclusion criteria: 
 
1) Aged over 18 years 
2) Willing and able to provide informed consent 
 
Control individuals who had any of these exclusion criteria were not recruited: 
 
1) Diagnosed with, or under investigation for an active neurological condition 
(however, individuals with previous neurological conditions that were no longer 
active, for example a prior transient ischemic attack or episodic migraine, were not 
excluded). 
2) Concomitant conditions or medications known to affect the parameters of interest 
(mainly diabetes, cancer, thyroid dysfunction, active inflammatory or infective 
conditions. However, those with other well-controlled chronic diseases such as 
hypertension and stable heart disease were not excluded). 
 
3.1.2 Ethical considerations  
 
The University of Queensland and The RBWH human research ethics committees 
approved all aspects of this study. Written informed consent was obtained from all 
participants prior to assessments.  
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3.2  Clinical Assessment 
 
3.2.1 Anthropometric assessment 
 
Demographic data including age and sex were recorded. Participants were asked to 
remove jewellery and eyeglasses and to wear underwear to minimize extracorporeal 
weight. Body mass was determined to the nearest 0.001kg (Cosmed USA Inc.). Hip 
circumference was measured to the nearest 0.5cm following established guidelines (WHO, 
2008). Height was measured to the nearest 0.5cm with a wall-mounted stadiometer (Novel 
Products Inc. Illinois, USA). Body mass index (BMI) was calculated as body mass divided 
by height squared (kg/m2). Body adiposity index (BAI) was calculated from height and hip 
circumference as described by Bergman et al (Bergman et al., 2011).  
 
BMI = Body Mass (kg) / Height (m)2  
 
BAI = [Hip circumference (cm) / Height (m)1.5 ] - 18 
 
3.2.2 Clinical assessment of ALS patients 
 
In ALS patients, the site of disease onset (either upper limb, lower limb, bulbar or 
respiratory) was recorded. Disease duration was defined as the interval between the onset 
of the first symptom reported by the patient and the day of metabolic assessment.  
 
ALS patients were asked whether they experienced significant weight loss 
(estimated to be more than ~10% of their original body weight) around the time of onset of 
the first ALS symptom. The answer given by the patient was confirmed with the medical 
records when possible.  
 
Respiratory function tests comprising measurement of seated and supine forced 
vital capacity (FVC) and the maximal sniff nasal pressure (SNIP) were performed within 4 
weeks of the metabolic assessment. Results were recorded as raw values and also 
expressed as a percentage of the predicted value.  
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The revised ALS functional rating scale (ALSFRS-R) (Cedarbaum et al., 1999) was 
recorded on the day of assessment. The ALSFRS-R bulbar, upper limb, lower limb and 
respiratory sub-scores were calculated as previously described by Pinto et al (Pinto and de 
Carvalho, 2015).  
 
The physical examination performed by the neurologist at the RBWH MND clinic at 
the time of ALS diagnosis was used to determine the upper motor neurone (UMN) and 
lower motor neurone (LMN) score as previously described (Ravits et al., 2007, Devine et 
al., 2016) (Table 3.1). Each limb was given an UMN and LMN score from 0–3 based on 
the degree of hyper-reflexia, spasticity and clonus, or degree of wasting and weakness 
respectively. Scores from each limb were summed to give a total UMN and LMN score, 
each out of 12.  
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Table 3.1 Scoring system used to quantify clinical UMN and LMN involvement in 
each limb.  
 
Notes: The grading of weakness refers to the Medical Research Council (MRC) scale for 
muscle power. Abbreviations: UMN, upper motor neurone; LMN, lower motor neurone. 
Table from Devine et al and Ravits et al (Devine et al., 2016) and (Ravits et al., 2007). 
 
 
 
 
Results
Of the 161 ubjects, 56% were males a d 93% had
no family history of ALS. Mean age at ED was 61
years (SD, 11 years). Disease onset was in the upper
limb in 54 subjects (33%), lower limb in 64 subjects
(40%) and bulbar region in 43 subjects (27%). At
the censorship date, 59% had died due to ALS,
while 66% had undergone an Event (NIV or death
due to ALS, whichever occurred first).
Univariate analysis was performed to identify
which variables were potential predictors of death or
an Event (Tables IIa and IIb). Gender, family
history, site of onset and riluzole use were screened
out as not being associated with survival. Increasing
age and shorter delay between onset and diagnosis
were both strongly associated with shorter time to
NIV or death (Table IIa).
Subjects with evidence of either bulbar or
respiratory involvement were more likely to progress
to NIV or death from that point in time (Exam to
Event), as well as showing reduced survival overall
(Onset to Event) (p50.01). Increasing the LMN
score, in the upper limbs, lower limbs or whole
body, was associated with reduced time to NIV or
death (p!0.001 for whole body score). In contrast,
increasing UMN scores were not significantly
associated with survival (Table IIb).
Variables identified as significant using univari-
ate analysis (age, bulbar involvement, diagnostic
delay and LMN score) were further assessed using a
Cox regression model. The covariate for respiratory
involvement had a singularity with time to Event,
and therefore was not considered further for Cox
regression. LMN upper limb and lower limb scores
were both colinear with the whole body LMN score,
and therefore were also not included separately for
Cox regression.
Older age, bulbar involvement and shorter diag-
nostic delay were all associated with reduced
covariate-adjusted survival (from onset or exam, to
either NIV or death; Table III). For example, a
patient 65 years of age or older has approximately
twice the risk of death or NIV compared with a
patient younger than 55 years of age. A patient with
bulbar involvement at the time of clinical examin-
ation has a two- to three-fold increase in risk of
death or NIV, compared with a patient in whom
bulbar function is preserved. For all variables except
diagnostic delay, hazard ratios were similar across all
of the four endpoints (Onset to Event, Onset to
Death, Exam to Event and Exam to Death). With
diagnostic delay, hazard ratios were higher when
survival was measured from an earlier time-point
(Onset vs. Exam), probably related to the longer
observation period.
Using Cox regression, it was confirmed that
higher whole body LMN score is strongly associated
with survival. A subject with a whole body LMN
score of 7–12 has four- to six-fold increased risk of
death or NIV, compared to subjects with mild LMN
involvement (Table III; Figure 1). At 18 months
from examination, the duration of a typical ALS
clinical trial (26), 73% of subjects with an LMN
score of 7–12 were deceased, whereas only 26% of
those with an LMN score of 3–6 were deceased.
Discussion
A key challenge facing ALS clinicians is the ability
to provide patients and carers with accurate
prognostic information. This is especially challen-
ging given the significant heterogeneity of ALS,
including diverse combinations of UMN and LMN
clinical signs (1,2). Furthermore, many assessment
tools and prospective biomarkers are either too
time-consuming or experimental to be applied in a
busy clinical setting (2,18). In this study, using a
simple bedside scoring system at a single time-point,
we have demonstrated that a higher burden of LMN
signs is strongly associated with lower survival from
the time of examination to an event (either NIV or
death). In contrast, the severity of UMN signs was
not associated with patient outcome.
Table I. Scoring system used to quantify clinical UMN and LMN
involvement in each limb.
UMN Score
0 No involvement
1 Definite, but trace involvement
" Reflexes preserved in a limb with weakness, or
" Slight increase in tone
2 Moderate involvement
" At least one reflex brisk (#3 on a 4-point
scale), or
" Moderate increase in tone, or
" Presence of an extensor plantar response
(in lower limb)
3 Significant and severe involvement
" All reflexes pathologically brisk with significant
transmission or clonus, or
" Significant spasticity, limiting ability to move
limb or walk
LMN Score
0 No involvement
1 Definite, but trace involvement
" Weakness #4/5, involving one or more
segments (with no segments54/5), and
" Mild wasting
2 Moderate involvement
" Weakness #3/5, involving one or more
segments (with no segment53/5), and
" Moderate wasting
3 Significant and severe involvement
" Little or no movement (LMN weakness !2/5)
involving one or more segments, and
" Severe wasting
186 M. S. Devine et al.
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3.3 Assessment of body composition 
 
3.3.1 Air displacement plethysmography (ADP) 
 
Whole body air displacement plethysmography (ADP) was selected for assessment of 
body composition as it is rapid and performed in a seated position. ADP is therefore 
suitable for use in the majority of ALS patients, even those with physical disability or 
respiratory dysfunction. ADP also avoids exposure to ionizing radiation (in contrast to 
DEXA), which was of particular ethical concern in the healthy control participants.  
 
On the same morning as the anthropometric assessment, body composition was 
determined by the BodPod system (Cosmed USA Inc.) according to standardized 
procedures (Fields et al., 2002, von Hurst et al., 2016). Full quality assurance and 
calibration procedures were carried out according to the manufacturers instructions each 
morning prior to testing. Assessment was performed at 8 am after an overnight (>12 
hours) fast. The following procedure was guided by prompts generated by the BodPod 
computer and the BodPod software automatically performed the calculations. 
 
Participants were asked to attend a second assessment of body composition 3 to 6 
months following their first assessment. 
 
3.3.2 ADP procedure  
 
Participants were asked to remove jewellery and eyeglasses before the test and to 
wear tight fitting underwear and a swimming cap during assessment to minimize 
extracorporeal volume and weight. Body weight to the nearest 0.001 kg was determined 
by the scale linked to the BodPod. The participant was then seated inside the BodPod 
chamber.  
 
The BodPod chamber is divided into two compartments separated by a common 
wall onto which a movable diaphragm is fixed (Figure 3.1). The front is the test chamber in 
which the subject sits and the back is the reference chamber. During a measurement, the 
BodPod is sealed by electromagnets on the door, while the diaphragm oscillates between 
 70 
the two chambers. Small volume changes are produced inside the chambers by oscillation 
of the diaphragm and the resulting pressure changes are detected.   
 
The volume of air inside the chamber was measured by applying Boyle’s Law, 
which states that at a constant temperature, volume (V) and pressure (P) are inversely 
related: P1/P2 = V2/V1. The volume of air in the test chamber was measured when the 
chamber was empty and then again when the participant was seated inside the chamber. 
Whole body volume was determined as the difference between the volume of air inside the 
chamber when the subject was inside, and the volume of air in the empty chamber.  
 
 
 
         
 
Figure 3.1 Schematic of the BodPod System (Cosmed USA, Inc). On the left, the front 
measurement chamber in which the participant sits, from Bayer College of Medicine 
website: https://www.bcm.edu/bodycomplab/bpodschemapage.htm. On the right, the 
components of the BodPod and diaphragm mechanism, from the Cosmed USA website: 
http://bodyknow.ca/index.php/the-bod-pod/how-it-works  
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The predicted thoracic gas volume was calculated according to the participant’s 
height and age as described by Crapo et al (Crapo et al., 1982). The thoracic gas volume 
was accounted for to determine the non-gas body volume. Body density was calculated 
according to the equation: Density = Mass divided by Volume.  
 
Following calculation of body density, fat mass (FM) and fat free mass (FFM) were 
calculated by the Bodpod software using the two-compartment body composition Siri 
model (Siri, 1961). Test results including whole body FM and FFM (percentage and mass 
in kg) were generated and displayed on the BodPod computer screen (Figure 3.2). 
 
 
 
 
 
Figure 3.2 Results screen generated by the BodPod system (Cosmed USA, Inc). The 
subject identifiers are blocked out in the right panel. 
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3.4  Assessment of resting energy expenditure 
 
3.4.1 Participant preparation 
 
On the same morning as the body composition assessment (described above in section 
3.3), participants underwent indirect calorimetry using the Quark RMR system (Cosmed 
USA Inc. Omnia software version 1.5) to measure resting energy expenditure (REE). 
Assessment of REE was performed in the morning to control for diurnal variation (Fredrix 
et al., 1990) and after an overnight (>12 hours) fast, to remove the component of energy 
expenditure that arises from the thermogenic effect of food (TEF) (D'Alessio et al., 1988). 
 
In the days prior to testing, to ensure that true resting conditions (Compher et al., 
2006, Haugen et al., 2007) were met, participants and/or patient carers were contacted by 
the investigator and asked to adhere to the following restrictions: 
 
1) For 12 hours prior to testing: 
a.  Fast i.e. consume nothing other than plain water 
b. Abstain from caffeine  
2) For at least 2 hours prior to testing: 
a.  Abstain from nicotine  
b. Abstain from physical exertion 
 
If participants were experiencing an inter-current illness in the days prior to assessment, 
for example a viral infection, the assessment was postponed until they were fully 
recovered. On arrival at the RBWH clinic, participants were transported in a wheelchair to 
the research building (to maintain a resting state) through indoor corridors (to avoid large 
variations in their surrounding temperature and negate the metabolic effects of changes in 
thermoregulation). Participants were maintained in a seated position for at least 15 
minutes prior to testing.  
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3.4.2 Prediction of REE 
 
The predicted REE (pREE) was computed by the BodPod software according to the 
modified Nelson equation taking into account FM and FFM (as shown in section 2.2.1, 
Table 2.2A). 
 
3.4.3 Indirect calorimetry procedure 
 
The classic open-circuit ventilated-hood technique (Figure 3.3) was used according to 
standard methods (Ferrannini, 1988, Blond et al., 2010, von Hurst et al., 2016). Thorough 
quality control procedures, including flow and gas calibration, were carried out according 
to manufacturer’s instructions prior to assessment each morning.  
 
The participant lay supine with a 30o head up angle with the canopy hood covering 
the face (Figure 3.4). The testing environment was controlled at 22oC and with minimal 
surrounding stimulation (to avoid an adrenergic stress response which could increase 
metabolic rate). The participant was instructed to breathe in a relaxed comfortable manner, 
to refrain from talking or moving and to stay awake during the recording.  
 
The fraction of carbon dioxide in the expired air (FeCO2) under the canopy was 
maintained between 0.9-1% by manual adjustment of the flow rate through the hood by 
the investigator. O2 consumption (VO2) and CO2 production (VCO2) were calculated as the 
difference between the expired air in the hood and room air. VO2 and VCO2 were 
measured every 10 seconds and energy expenditure was determined by COSMED Omnia 
V1.5 software according to the abbreviated Weir equation (Weir, 1949) (see section 
2.2.5).  
 
Recordings were collected for at least 20 minutes. The recording from the first 5 
minutes of assessment, during which the participant became accustomed to the 
environment, was excluded from analysis. A stable epoch of no less than 15 minutes was 
selected to calculate the average REE in kcal/day. 
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Fig 3.3 Schematic of the indirect calorimetry system. This shows the canopy method in 
a spontaneously breathing subject (other systems exist for use in ventilated subjects). The 
subject is placed under a clear canopy with a plastic drape to avoid air leakage. The flow 
generator creates a constant outward flow through the canopy. The exhaled breath is 
diluted by the constant flow from the flow generator (L/min), and collected by the 
calorimeter for gas analysis. The fraction of expired air that is oxygen (FeO2) and carbon 
dioxide (FeCO2) is measured by the gas analyzer. The fraction of inspired air that is 
oxygen (FiO2) and carbon dioxide and (FiCO2) are measured in the ambient air. From 
these values, the volumes of consumed O2 (VO2) and produced CO2 (VCO2) are 
calculated. These values are used to calculate EE using the Weir equation (see section 
2.2.5). (Arrows, respiratory gas flow; solid line, gas sampling; dotted line, signal for flow 
analysis). Adapted from Oshima et al (Oshima et al., 2016). 
 
 
 
 
Fig. 1. Schematic presentation of indirect calorimetry used in patients on mechanical ventilation and on those breathing spontaneously. a) Breath by breath: Respiratory gas
composition and ﬂow are measured cont nuously by connecting the gas analyzers to the ventilator circuit. The signals received by the gas analyzers and ﬂow meters are syn-
chronized to calculate the oxygen consumption (VO2 L/min) and CO2 production (VCO2 L/min) as the difference between the volumes of inhaled and exhaled O2 and CO2 per breath
by integral calculations. The Haldane transformation [Table 1] is used to calculate the inhaled gas volume from exhaled gas volume measurement. The Weir's equation [Table 1] is
used to calculate EE (kcal/d) per breath, and averaged for the duration of the measurement. The system is highly responsive to the dynamic changes of the EE, but prone to errors
due to the response time of the gas analyzers and software. b) Mixing chamber: The O2 concentration of inhaled air (FiO2) is ﬁrst measured. Exhaled gas is collected into the mixing
chamber, where it is physically averaged and analyzed for O2 (FeO2) and CO2 (FeCO2) concentrations. The collected gas is eliminated through an independent chamber where the gas
ﬂow (Q) is kept constant at 40e45 L/min, to dilute the exhaled gas from the mixing chamber with the ambient air. CO2 in the diluted gas (FedCO2) is measured to calculate the CO2
production (VCO2, L/min) by multipl ing the concentration by the ﬂow (VCO2¼ FedCO2 " Q). An equation using the Haldane t ansformation allows the calculation of the respiratory
quotient (RQ) from the measured O2 and CO2 values (RQ ¼ (1#FiO2)/[(FiO2#FeO2)/FeCO2#FiO2]), and thus enables the calculation of the oxygen consumption (VO2, L/min;
VO2 ¼ VCO2/RQ). This unique method used in the Deltatrac Metabolic Monitor® (Datex, Finland) enables VO2 and VCO2 measurements without measuring the ﬂow of the exhaled
gas, which usually introduces technical difﬁculties. c) Canopy: The canopy is used to measure EE in spontaneously breathing subjects. The subject is placed under a clear canopy
with a plastic drape to avoid air leakage. Calorimeters feature constant ﬂow generator to cre te an outward ﬂow through the canopy. The exhaled breath by the subject is diluted by
the constant ﬂow Q (L/min), and collected by the calorimeter for gas analysis (FedO2, FedCO2), and enables calculations of VO2 and VCO2 [Table 1]. FiO2 and FiCO2 are either assumed
as ambient air values or measured, depending on the calorimeter. These values are used to calculate the EE using the Weir's equation. (1: ﬂow analysis, 2: FiO2, 3: FiCO2, 4: FeO2,
5:FeCO2, 6:FedCO2, 7: FedO2; small arrows: respiratory gas ﬂow, solid line: gas sampling, dotted line: signal for ﬂow analysis, small arrows: respiratory gas ﬂow, bold arrow:
constant ﬂow).
Table 4
Technologies used in commercially available calorimeters.
Patient condition Patient application Technology Practical characteristics (advantages/disadvantages)
Spontaneous Breathing Canopy Constant ﬂow dilution Patient discomfort minimum
Difﬁcult to measure with O2 supplementation
Facemask Breath by breath or mixing chamber Supports O2 and mask ventilation
Patient discomfort, risk of leak
Mechanical Ventilation In-circuit Breath by breath Small device, fast response
Prone to error in calculation, dead space &
resistance of the measurement components
Gas collection Mixing chamber Stable measurements, validated in literature
Large devices, difﬁcult to disinfect
T. Oshima et al. / Clinical Nutrition xxx (2016) 1e124
Please cite this article in press as: Oshima T, et al., Indirect calorimetry in nutritional therapy. A position paper by the ICALIC study group, Clinical
Nutrition (2016), http://dx.doi.org/10.1016/j.clnu.2016.06.010
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Figure 3.4 A test subject undergoing indirect calorimetry. This picture shows the 
open-circuit canopy dilution technique employed in this thesis (Quark RMR, Cosmed 
USA).  
 
3.5 Longitudinal assessment 
 
ALS patients were invited to attend a second visit 3–6 months following their first 
assessment. The second visit comprised repeat anthropometric and ADP assessment of 
body composition and assessment of disease progression as measured by the ALSFRS-
R.  
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3.6 Statistical methods 
 
Statistical analysis was performed by the investigator using Prism software version 7 
(Graphpad Inc, CA, USA). For all outcomes, a p value <0.05 was considered statistically 
significant. 
 
3.6.1 Statistical methods for objective one 
 
Correlations between anthropometric measures and FM in ALS patients and controls 
Linear regression analysis was used to examine the relationships between each 
anthropometric measurement (BMI and BAI) and percent FM derived from ADP. Pearson’s 
correlation coefficient from univariate analysis was also determined for each relationship.  
 
Agreement between anthropometric measures and FM in ALS patients and controls 
The agreement between each anthropometric measure and percent FM derived from ADP 
was assessed by the Bland-Altman approach (Bland and Altman, 1986). The difference 
versus the mean of the two methods was plotted for each participant. The Bland-Altman 
analysis evaluates the bias between the mean differences of the two methods, and 
estimates an agreement interval, within which 95% of the differences of one method fall, 
compared to the other (Giavarina, 2015). In each plot the results were compared to the 
line of equality, which reflects complete agreement between methods.  
 
Longitudinal changes in anthropometric measures and FM in ALS patients 
 The net change in BMI, BAI and percent FM derived from ADP between longitudinal 
assessments was calculated for each ALS patient.  Linear regression analysis was used to 
examine the strength of the relationship between a change in BMI and BAI versus percent 
FM derived from ADP. 
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3.6.2 Statistical methods for objective two 
 
Metabolic Index to define hypermetabolism: 
pREE was derived from the modified Nelson equation (Chapter 2 section 2.2.1 table 
2.2A). Metabolic index was calculated as: 
 
measured REE (mREE) / predicted REE (pREE) x 100 
 
Hypermetabolism was defined as a metabolic index ≥ 120 (Perseghin et al., 2002). In this 
study, participants with a metabolic index <120 were defined as normometabolic. The 
proportion of each cohort that reached the definition for hypermetabolism was calculated. 
The metabolic indices of the ALS and control cohorts were displayed in a frequency 
histogram.  
 
Clinical factors associated with hypermetabolism:  
Demographic, energy expenditure, body composition and clinical parameters were 
compared between normometabolic and hypermetabolic ALS patients. Quantitative means 
were compared using an unpaired Student’s t-test and ratios or percentages were 
compared using Fishers exact test.  
 
Linear regression analysis was used to examine the relationships between the metabolic 
index and demographic, body composition and clinical parameters. Pearson’s correlation 
coefficient from univariate analysis was also determined for each relationship.  
 
Longitudinal analysis: 
 For ALS patients who attended a second assessment, the individual net changes in 
ALSFRS-R scores and body composition data between the first and second assessment 
were calculated. Quantitative mean changes were compared between normometabolic 
and hypermetabolic patients using an unpaired Student’s t test. 
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Chapter 4: Results and summary of findings 
 
4.1 Results for objective 1 
 
A version of this section of the thesis was published in IOANNIDES, Z. A., STEYN, F. J., 
HENDERSON, R. D., MCCOMBE, P. A. & NGO, S. T. 2017. Anthropometric measures are 
not accurate predictors of fat mass in ALS. Amyotrophic Lateral Sclerosis and 
Frontotemporal Degeneration, published online 27 Apr 2017. This paper can be found in 
Appendix 2. 
 
4.1.1 Participant demographics and body composition data 
 
44 ALS patients and 35 age- and sex-matched healthy control participants 
underwent anthropometric and body composition analysis as described in Chapter 3. 
Baseline demographic and clinical data is shown in table 4.1. No ALS patients were 
receiving enteral nutrition at the time of their first assessment.  
 
Anthropometric and fat mass (FM, derived from air displacement plethysmography, 
ADP) data is shown in table 4.2. There were no significant differences in body mass index 
(BMI) or body adiposity index (BAI) between the ALS and control cohorts. Although a 
lower total body mass and higher percentage FM was observed in the ALS cohort, this did 
not reach statistical significance. 
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Table 4.1 Demographic and clinical data of 35 control and 44 ALS participants.  
  Control (n=35) ALS (n=44) p value 
Male:Female (n) 
 
25:10 (71.43% male) 32:12 (72.73% male)  >0.99 
Age (years)    
 
59.48±1.18 (46.64-73.74) 61.09±1.32 (46.02-79.55) 0.37 
Age of males (years) 
 
59.35±1.53 (46.64-73.74) 59.49±1.61 (46.02-79.55) >0.99 
Age of females (years) 
 
59.86±1.37 (52.78-66.54) 65.37±1.81 (55.79-74.83) 0.23 
Time Since Diagnosis 
(months) 
 N/A 9.90±1.58 (0.77-47.00)  N/A 
ALSFRS-R (of 48) 
 
 N/A 38.50±0.64 (28.00-46.00)  N/A 
Notes: Data presented as mean ± SEM (range). Exact age at assessment was calculated in years 
from date of birth to date of assessment. p value for comparison of controls and ALS patients; 
quantitative means compared using an unpaired Student’s t-test, age ratios compared using the 
Fishers exact test. Abbreviations: ALSFRS-R, the revised Amyotrophic Lateral Sclerosis functional 
rating scale; N/A, not assessed; SEM, standard error of mean. 
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Table 4.2 Anthropometric and fat mass data of 35 control and 44 ALS participants.  
 Control (n=35) ALS (n=44) p value 
Body Mass (kg) 82.23±3.11 (50.61-119.90) 76.37±2.16 (52.19-112.80) 0.12 
BMI (kg/m2) 26.65±0.79 (17.93-37.25) 25.64±0.52 (19.17-34.13) 0.28 
Hip circumference (cm) 
 
98.91±1.84 (81.00-123.00)  98.75±1.25 (81.00-116.00) 0.94 
BAI 24.84±0.81 (16.42-43.25) 25.93±0.79 (15.96-37.39) 0.34 
Fat mass (%) 30.55±1.36  (10.00-53.60) 34.01±1.73 (7.20-55.60) 0.15 
Fat mass (kg) 26.89±2.05 (5.07-57.97) 26.49±1.52 (5.63-51.46) 0.88 
Notes: Data presented as mean ± SEM (range). p value for comparison of controls and ALS 
patients using an unpaired Student’s t-test. Abbreviations: BAI, body adiposity index; BMI, body 
mass index; Fat mass determined by air displacement plethysmography. 
 
 
 
4.1.2 Correlations between anthropometric measures and fat mass  
 
Positive correlations were observed between BMI and percentage FM in controls (r2=0.34; 
r=0.59; p<0.01) and ALS patients (r2=0.29; r=0.54; p<0.01) as shown in figure 4.1A. 
Similarly, positive correlations were observed between BAI and percentage FM in controls 
(r2=0.61; r=0.78; p<0.01) and ALS patients (r2=0.56; r=0.75; p<0.01) as shown in figure 
4.1B. The slopes of the regression lines of the ALS and control cohorts were significantly 
different (for comparison of BMI vs. FM slopes, p=0.03 figure 4.1A, and for comparison of 
BAI vs. FM slopes, p=0.04 figure 4.1B).  
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Figure 4.1 Correlations between percentage fat mass and body mass index (A) and 
body adiposity index (B).  The slopes of the regression lines of the ALS and control 
cohorts were significantly different [for comparison of BMI vs. FM slopes, p=0.03 (A), for 
comparison of BAI vs. FM slopes, p=0.04 (B)]. Abbreviations: BAI, body adiposity index; 
BMI, body mass index. Fat mass as measured by air displacement plethysmography. 
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4.1.3 The agreement between anthropometric measures and fat mass 
 
Bland-Altman analyses to examine the agreement between each anthropometric 
measurement and percentage FM, revealed a positive mean bias (MB) for all comparisons 
(figure 4.2A to 4.2D). The MBs of the ALS cohort were greater than those of the control 
cohort. For analyses comparing BMI to percentage FM, the MB of Controls = 4.22 and the 
MB of ALS patients = 8.38.  For analyses comparing BAI to percentage FM, the MB of 
Controls = 5.91 and MB of ALS patients = 8.08.  
 
The 95% confidence intervals of limits were greater in the ALS analyses (-12.14 to 
28.89 for analyses comparing BMI to percentage FM and -9.06 to 25.23 for analyses 
comparing BAI to percentage FM, figure 4.2C and D) than the control analyses (-7.41 to 
15.84 for analyses comparing BMI to percentage FM and -3.22 to 15.04 for analyses 
comparing BAI to percentage FM figure 4.2A and B).  
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Figure 4.2 Bland–Altman analyses of anthropometric measures against fat mass. 
Controls are indicated by white circles (A and B) and ALS patients are indicated by blue 
circles (C and D). The mean bias (MB; broken red line) illustrates the average discrepancy 
between methods. Broken grey lines illustrate the 95% confidence interval of limits of 
agreement (mean bias ± 2 STD). Abbreviations: ALS, amyotrophic lateral sclerosis; BAI, 
body adiposity index; BMI, body mass index; MB, mean bias; STD, standard deviation. Fat 
mass refers to percentage fat mass determined by air displacement plethysmography. 
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4.1.4 Longitudinal assessment of ALS patients 
 
29 ALS patients (22 male and 7 female) were re-assessed ~6 months (mean 5.65 ± 
0.40, range of 2.80 to 9.73 months) following their initial assessment. Demographic, 
anthropometric and fat mass data is shown in Table 4.3. The mean ALSFRS-R score 
significantly decreased between assessments, reflecting a decline in function between the 
first and second assessment. One patient (patient 4 in table 4.4) commenced regular 
enteral nutrition via a percutaneous endoscopic gastrostomy (PEG) between 
assessments. 
 
While the mean BMI did not change, the mean BAI increased between 
assessments (p=0.04). However, the increase in mean BAI was by less than 1 unit. The 
mean percentage and total FM (kg) did not change between assessments, however, 
individual increases or decreases in FM were observed. The individual changes in BMI, 
BAI and fat mass are shown in figure 4.3 and table 4.4. There was a wide range of 
change in both FM (kg) and percentage FM over the ~6 month interval. The net change of 
FM (kg) ranged from a loss of 9.36kg fat to a gain of 6.96kg fat (Table 4.4).  
 
The change in FM was not consistently reflected by either anthropometric 
measurement. In some individuals the direction of change of BMI or BAI was opposite to 
the direction of change in FM (Figure 4.4 and table 4.4). 
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Table 4.3 Longitudinal demographic, anthropometric and fat mass data of 29 ALS 
patients.  
  1st assessment 2nd assessment p value 
Age at Assessment 
(years) 
60.60±1.65 (46.04-79.55) 61.06±1.65 (46.49-79.82) N/A  
Time from Diagnosis 
(months) 
10.84±2.12 (0.90-47.10) 16.48±2.14 (4.60-51.07) N/A   
ALSFRS-R (out of 48) 38.48±0.75 (28.00-45.00) 36.79±0.77 (26.00-45.00) <0.01 
Body Mass (kg) 77.01±2.78 (55.50-112.80) 76.36±3.02 (55.64-114.90)  0.43 
BMI (kg/m2) 25.45±0.68 (20.18-34.13) 25.25±0.80 (18.10-34.78) 0.46 
Hip circumference (cm) 97.12±1.66 (81.00-116.00) 97.91±1.83 (82.50-114.00) 0.42 
BAI 24.70±0.96 (15.96-35.63) 25.40±1.05 (15.93-36.80) 0.04 
Fat mass (%) 33.07±2.00 (11.70-50.40) 32.90±2.13 (7.70-49.80) 0.82 
Fat mass (kg) 25.81±1.93 (6.94-51.46) 25.66±2.07 (4.42-49.84) 0.82 
Notes: Data presented as mean ± SEM (range). p value for comparison of measures between 1st 
and 2nd assessment using a paired Student’s t-test. Abbreviations: ALSFRS-R, the revised 
Amyotrophic Lateral Sclerosis functional rating scale; BAI, body adiposity index; BMI, body mass 
index; N/A, not assessed. Fat mass determined by air displacement plethysmography.  
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Figure 4.3 Longitudinal changes in fat mass and anthropometric measures. Scatter 
plots showing net changes in percentage fat mass (A) and BMI and BAI (B) in 29 ALS 
patients over a ~6 months interval (mean 5.65 ± 0.40, range of 2.80 to 9.73 months). 
Abbreviations: BAI, body adiposity index, BMI, body mass index; FM, fat mass determined 
by air displacement plethysmography. 
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Table 4.4 Individual longitudinal anthropometric and fat mass data of 29 ALS 
patients. Net change in values (Δ) from first assessment to the second assessment after a 
~6 month interval (mean 5.65 ± 0.40, range of 2.80 to 9.73 months). 1st refers to the 
measure at the first assessment.  
Patient 
number 
and sex 
Assessment 
interval 
(months) 
1st BMI Δ BMI 1st 
BAI  
Δ BAI 1st FM 
(%) 
Δ FM  
(%) 
1st FM  
(kg) 
Δ FM  
(kg) 
1 M 6.30 26.78 1.07 25.37 0.42 29.50 2.40 25.00 3.14 
2 M 5.30 20.94 1.18 25.89 -1.33 15.70 8.70 9.70 6.28 
3 M 9.57 23.07 -1.05 18.64 0.07 27.10 -1.50 21.86 -1.86 
4 M* 7.50 22.44 -3.02 19.46 -0.66 18.10 -10.40 12.01 -7.59 
5 M 2.80 24.16 0.46 23.09 2.52 28.80 1.60 22.20 1.63 
6 M 6.77 27.33 0.86 23.02 3.81 33.00 0.90 28.42 1.68 
7 F 7.70 31.45 -0.08 25.97 -1.18 31.60 -0.60 34.58 -0.73 
8 M 9.73 25.72 -0.75 24.76 -2.16 39.50 -0.60 31.10 -1.38 
9 F 8.40 32.18 0.67 32.11 -0.86 44.30 0.10 43.64 1.00 
10 M 7.27 25.72 -5.07 21.16 0.42 30.30 -6.90 24.68 -9.36 
11 F 8.33 20.18 -0.25 18.07 0.67 11.70 -0.30 6.94 -0.26 
12 M 7.80 23.50 0.38 21.99 0.00 42.20 2.10 29.71 1.99 
13 F 6.77 24.23 -0.49 21.31 0.00 30.70 0.50 22.76 -0.10 
14 F 6.07 27.45 0.93 25.76 1.53 41.20 2.00 34.00 2.92 
15 M 6.60 22.49 -0.14 22.41 0.00 27.70 -0.90 17.60 -0.66 
16 F 5.87 23.08 0.23 18.95 0.85 21.20 1.60 15.34 1.31 
17 M 5.43 21.67 -0.66 15.96 0.98 12.30 -1.30 9.28 -1.24 
18 M 2.80 34.13 0.65 27.69 0.41 45.60 -2.20 51.46 -1.62 
19 M 3.53 20.54 -2.44 16.94 -1.01 22.90 -5.30 15.76 -5.11 
20 F 3.23 28.27 -0.47 26.35 -0.29 34.10 -2.80 27.40 -2.96 
21 M 3.27 27.76 0.88 21.42 2.76 33.20 0.80 31.87 1.83 
22 M 2.87 31.19 0.30 25.69 0.62 37.70 1.20 38.12 1.51 
23 M 3.07 24.64 1.16 30.31 5.26 34.60 8.50 22.77 6.96 
24 M 5.23 27.34 -0.78 35.63 -1.03 43.10 -1.50 28.68 -1.77 
25 M 6.60 24.85 -0.53 29.26 0.23 47.00 -0.40 32.57 -0.97 
26 M 3.53 22.10 -1.78 28.49 -1.11 49.40 -5.00 28.82 -4.99 
27 M 4.37 25.49 1.39 33.34 2.54 43.50 1.00 27.35 2.14 
28 M 3.97 27.87 1.25 33.89 2.91 50.40 -0.60 36.83 1.23 
29 M 3.03 21.54 0.33 23.31 3.93 32.60 4.00 18.07 2.54 
Notes: *Patient number 4 began receiving regular enteral nutrition via a percutaneous 
endoscopic gastrostomy (PEG) 5 months after the first assessment. Abbreviations: BAI, 
body adiposity index; BMI, body mass index; F, female; FM, fat mass determined by air 
displacement plethysmography; M, male. 
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Positive correlations were observed between the change in both anthropometric 
measurements and the change in percentage FM. A change in BMI versus a change in 
percentage FM is shown in figure 4.4A (r2=0.62 r=0.79 p<0.01). A change in BAI versus a 
change in percentage FM is shown in figure 4.4B (r2=0.20 r=0.44 p=0.02). 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4.4 Correlations between the net changes in anthropometric measures and 
percentage fat mass. Linear regression showing 95% confidence band of line of best fit 
for change in BMI (A) or change in BAI (B) relative to change in the percentage fat mass 
determined by air displacement plethysmography. Male and female ALS patients are 
indicated in blue and red respectively. Abbreviations: BAI, body adiposity index; BMI, body 
mass index; FM, fat mass. 
 
 
 
 
 
 
 
 
 
-15 -10 -5 0 5 10
-6
-4
-2
0
2
4
6
Change in percentage FM
C
ha
ng
e 
in
 B
M
I
r2=0.62
r=0.79
p<0.01
Male
Female
-15 -10 -5 0 5 10
-6
-4
-2
0
2
4
6
Change in percentage FM
C
ha
ng
e 
in
 B
AI
r2=0.20
r=0.44
p=0.02
Male
Female
A B
 89 
 
4.1.5 Summary of findings 
 
Using ADP as the standard, the accuracy of BMI and BAI in predicting adiposity was 
assessed in 44 ALS patients. The accuracy in ALS patients was compared to that of 35 
healthy age- and sex-matched controls. Longitudinal assessments were performed in 29 
ALS patients to determine the accuracy of BMI and BAI in predicting changes in FM over 
time. 
  
While BMI and BAI correlated with percentage FM, Bland-Altman analyses showed 
that there was a lack of agreement between either anthropometric measure and 
percentage FM. BMI and BAI were both associated with a positive bias when compared to 
percentage FM. Furthermore, comparisons of the results between the ALS patients and 
healthy matched controls suggest that both anthropometric measurements are worse 
predictors of FM in ALS than in controls.  
 
In a longitudinal assessment of ALS patients there was no change in the mean FM, 
although individual changes in FM ranging from a loss of 9.36kg to a gain of 6.96kg were 
observed. A change in BMI and BAI correlated with a change in FM. However, neither BMI 
nor BAI consistently reflected the change in FM. Indeed, the direction of change of BMI 
and BAI was opposite to the direction of change in FM in some patients.  
 
These results indicate that an isolated measure of BMI and BAI is not an accurate 
indicator of adiposity in ALS and that assessing longitudinal changes in these 
anthropometric measures could be misleading. 
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4.2 Results for objective 2 
 
Fifty ALS patients and 50 age- and sex-matched controls underwent assessment of body 
composition and resting energy expenditure (REE) as described in Chapter 3. 
 
4.2.1 Clinical characteristics of the ALS patients 
 
The clinical characteristics of the ALS patients are shown in Table 4.5. In the majority of 
patients, the lower limbs were the site of onset of disease.  One female ALS patient, aged 
72, was known to be a carrier of the C9orf-72 mutation and had a diagnosis of 
frontotemporal dementia (FTD). The mean duration of disease from symptom onset was 
25.84 ± 2.71 (2.53–89.73) months at the time of assessment. The average ALSFRS-R 
score was 38.04 ± 0.55 (28–46). Eighteen patients (36%) reported significant weight loss 
at the time of onset of first ALS symptom. One ALS patient had been receiving enteral 
nutrition via a PEG for 2 months prior to assessment.  
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Table 4.5 Clinical data for 50 ALS patients.  
  ALS  
Total cohort                            
(n=50) 
ALS  
Male cohort                         
(n=34) 
ALS  
Female cohort                       
(n=16) 
Disease parameters    
UL onset n (%) 14 (28.00) 12 (35.29) 2 (12.50) 
LL onset n (%) 21 (42.00) 13 (38.24) 8 (50.00) 
Bulbar onset n (%) 14 (28.0) 8 (22.53) 6 (37.50) 
Resp onset n (%) 1 (2.00) 1 (2.94) 0 (0.00) 
Disease duration 
(months) 
25.84±2.71  
(2.53-89.73) 
26.65±3.37  
(2.53-89.73) 
24.14±4.66  
(6.83-82.47) 
ALSFRS-R scores    
Total score (of 48) 38.04±0.55 (28-46) 38.47±059 (32-46) 37.13±1.17 (28-43) 
Bulb score (of 12) 10.28±0.29 (3-12) 10.38±0.32 (3-12) 10.06±0.61 (3-12) 
UL score (of 8) 6.30±0.26 (2-8) 6.21±0.32 (2-8) 6.50±0.43 (3-8) 
LL score (of 8) 4.50±0.29 (1-8) 4.94±0.33 (3-8) 3.56±0.52 (1-8) 
Resp score (of 12) 11.18±0.22 (6-12) 11.00±0.32 (6-12) 11.56±0.18  
(10-12) 
Clinical examination 
scores 
   
UMN score (of 12) 6.28±0.42 (0-12) 6.50±0.53 (0-12) 5.80±0.74 (0-10) 
LMN score (of 12) 3.40±0.35 (0-11) 3.32±0.39 (0-8) 3.56±0.74 (0-11) 
Respiratory function 
tests 
   
Seated FVC  
(% of predicted) 
91.64±2.84  
(59-129) 
93.76±3.26  
(64-129) 
87.13±5.55  
(59-127) 
Postural change in 
FVC (%) 
-11.34±1.62  
(-55.38-8.23) 
-11.96±1.95  
(-55.38-2.57) 
-9.95±2.95  
(-34.44-8.23) 
SNIP  
(% of predicted) 
60.15±3.42  
(16-108) 
60.29±4.65  
(16-108) 
59.88±4.67  
(30-99) 
Notes: Data presented as mean ± SEM (range). Disease duration refers to the interval in months 
between symptom onset and assessment. ALSFRS-R sub-scores determined as described by 
Pinto et al (Pinto and de Carvalho, 2015). Clinical examination scores (UMN and LMN scores) 
determined as described by Ravits et al (Ravits et al., 2007). Abbreviations: UL, upper limb; LL, 
lower limb; ALSFRS-R, the revised Amyotrophic Lateral Sclerosis functional rating scale; Bulb, 
bulbar; Resp, respiratory; UMN, upper motor neurone; LMN, lower motor neurone; FVC, forced 
vital capacity; SNIP, maximal sniff nasal inspiratory pressure.  
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4.2.2 Body composition and REE data 
 
Demographic and body composition data of all participants are presented in Tables 4.6 A 
to C. There was no difference between the control and ALS cohorts in sex ratio or age. 
The mean weight and BMI of the ALS cohort were lower than the controls, however, these 
did not reach statistical significance (Table 4.6 A).  
 
The mean fat free mass (FFM) in kg of ALS patients was significantly lower than 
that of controls (Table 4.6 A). The mean weight, BMI and FFM (kg) of the male ALS cohort 
were significantly lower than the male control cohort (table 4.6 B). When compared to the 
female control cohort, the mean percentage FFM of the female ALS cohort was lower and 
the mean percentage FM was higher. 
 
REE data for the total, male and female cohorts of the ALS and control participants 
is shown in Table 4.6 A to C. The predicted REE (pREE, derived from the modified 
Nelson equation as described in Chapter 2 section 2.2.1 and table 2.2) was significantly 
lower in the total, male and female ALS cohort compared to the respective control cohort. 
There was no difference in the mean mREE between each ALS cohort and the respective 
control cohort. The mean mREE corrected for FFM (REE/FFM) of the each ALS cohort 
was higher than the respective control cohort, however, only the difference between the 
REE/FFM of the male ALS and male control cohorts was statistically significant.  
 
Metabolic index data [measured REE (mREE) / pREE x 100] is shown in table 4.6 
A to C).  The mean metabolic index of the total ALS cohort was higher than that of the 
total control cohort however this did not reach statistical significance. The metabolic index 
of the male ALS cohort was significantly higher than that of the male control cohort 
(p<0.01).  
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Tables 4.6 A to C: Age, body composition and resting energy expenditure data for 
the control and ALS cohorts. Table A shows data for the total ALS and control cohorts, 
B shows data for the male cohorts and C shows data for the female cohorts.  
 
Table 4.6 A. Age, body composition and resting energy expenditure data for the 
total control and total ALS cohorts 
 
 
 
 
 
 
 
 
 
  Control 
Total cohort (n= 50) 
ALS 
Total cohort (n=50) 
p value 
Age (yrs) 59.47±1.06 (42.41-74.05) 61.74±1.21 (46.02-79.55) 0.16 
Body composition    
Weight  (kg)  82.42±2.23 (52.15-119.90) 76.66±2.06 (48.77-112.80) 0.06 
BMI (kg/m) 27.03±0.59 (19.27-37.25) 25.96±0.60 (19.00-42.49) 0.21 
FFM (kg) 55.91±1.65 (35.26-74.49) 50.27±1.56 (29.53-74.82) 0.01 
FM (kg) 26.57±1.38 (11.79-55.01) 27.63±1.58 (3.10-66.25) 0.62 
FFM (%) 68.11±1.23 (46.30-85.00) 64.68±1.66 (35.10-92.80) 0.10 
FM (%) 31.87±1.23 (15.00-53.70) 35.31±1.67 (7.20-64.90) 0.10 
Resting energy 
expenditure data 
 
  
pREE 1549±43.27 (1016-2105) 1392±40.03 (878-2070) <0.01 
mREE (kcal per day) 1669±53.47 (817-2413) 1602±64.00 (641-2532) 0.43 
mREE/FFM (kcal/kg 
per day) 
30.02±0.63 (17.93-40.14) 
32.12±1.00 (11.57-45.59) 0.08 
Metabolic Index 107.81±2.04 (65.20-139.27) 114.47±3.05 (62.48-147.73) 0.07 
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Table 4.6 B. Age, body composition and resting energy expenditure data for the 
male control and male ALS cohorts 
 
 
 
 
 
 
 
 
 
  Control 
Male cohort (n= 34) 
ALS 
Male cohort (n=34) 
p value 
Age (yrs) 58.65±1.37 (42.41-73.74) 60.39±1.60 (46.02-79.55) 0.41 
Body composition    
Weight  (kg)  89.50±1.95 (67.42-119.90) 80.92±2.40 (52.19-112.80) <0.01 
BMI (kg/m) 27.90±0.54 (20.36-35.04) 25.90±0.65 (19.00-34.13) 0.02 
FFM (kg) 62.89±1.08 (46.13-74.49) 55.93±1.22 (40.64-74.82) <0.01 
FM (kg) 26.69±1.49 (11.79-52.80) 25.87±1.84 (3.10-51.46) 0.73 
FFM (%) 70.77±1.15 (52.20-85.00) 69.36±1.73 (54.40-92.80) 0.50 
FM (%) 29.23±1.15 (15.00-47.80) 30.63±1.74 (7.20-45.60) 0.50 
Resting energy 
expenditure data 
   
pREE 1729±29.23 (1318-2105) 1547±32.53 (1169-2070) <0.01 
mREE (kcal per day) 1870±39.52 (1246-2413) 1827±54.60 (1235-2532) 0.52 
mREE/FFM (kcal/kg 
per day) 
29.82±0.53 (23.61-37.68) 32.78±0.95 (23.56-42.19) <0.01 
Metabolic Index 
108.25±1.67 (87.68-131.87) 
118.23±2.83  
(89.49-147.46) 
<0.01 
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Table 4.6 C. Age, body composition and resting energy expenditure data for the 
female control and female ALS cohorts 
Notes for tables 4.6 A to C: All data is presented as mean ± SEM (range). Metabolic index, 
mREE/pREE x 100. p values from an unpaired students t-test. Abbreviations: ALSFRS-R, 
the revised ALS functional rating scale; BMI, body mass index; FFM, Fat-free mass; FM, 
fat mass; kcal, kilocalories; mREE, measured REE; pREE, predicted REE according to the 
modified Nelson equation (as described in Chapter 2 section 2.2.1 and table 2.2).  
 
 
 
 
  Control 
Female cohort (n= 16) 
ALS 
Female cohort (n=16) 
p value 
Age (yrs) 61.21±1.57  (52.81-74.05) 64.60±1.47 (55.79-74.83) 0.12 
Body composition    
Weight  (kg)  67.39±3.27 (52.15-102.60) 67.60±2.40 (48.77-102.10) 0.96 
BMI (kg/m) 25.20±1.36 (19.27-37.25) 26.09±1.31 (19.29-42.49) 0.64 
FFM (kg) 41.07±0.82 (35.26-47.64) 38.23±1.93 (29.53-62.93) 0.19 
FM (kg) 26.32±3.00 (12.58-55.01) 31.37±2.85 (17.47-66.25) 0.23 
FFM (%) 62.46±2.46 (46.30-76.00) 54.74±2.13 (35.40-67.40) 0.02 
FM (%) 37.49±2.48 (15.00-47.80) 45.26±2.14 (32.60-64.90) 0.02 
Resting energy 
expenditure data 
   
pREE 1166±26.48 (1016-1451) 1063±28.30 (878-1255) 0.01 
mREE (kcal per day) 1240±62.64 (817-1619) 1125±74.79 (641-1562) 0.25 
mREE/FFM (kcal/kg 
per day) 
30.42±1.66 (17.93-40.14) 32.78±0.95 (23.56-42.19) 0.93 
Metabolic Index 
106.87±5.43 (65.20-139.27) 
106.46±7.17  
(62.48-147.73) 
0.96 
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4.2.3 The incidence of hypermetabolism 
The incidence of hypermetabolism (defined as metabolic index ≥ 120) is shown in 
Figure 4.5 A. Hypermetabolism was observed in 8 (16%) of the controls and 20 (40%) of 
the ALS patients. Four (50%) of the hypermetabolic controls were males and 15 (75%) of 
the hypermetabolic ALS patients were males. The pattern and range of spread of 
metabolic index in both cohorts are shown in Figure 4.5 B, where it can be seen that the 
frequency histogram of the ALS cohort is shifted to the right compared to that of the 
control cohort. The female ALS patient with FTD had a metabolic index of 66.36. 
 
 
Figure 4.5 Metabolic index of controls and ALS patients. (A) Bar chart showing the 
incidence of hypermetabolism (defined as metabolic index ≥ 120) and normometabolism 
(defined as metabolic index < 120). (B) Frequency histogram showing the spread of 
metabolic index in control (white bars) and ALS (blue bars) cohorts. The distribution of the 
ALS cohort is shifted to the right compared to that of the control cohort. Abbreviation: ALS, 
amyotrophic lateral sclerosis. 
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4.2.4 Clinical correlates of hypermetabolism 
 
Comparison of the characteristics of hypermetabolic and normometabolic ALS patients  
Table 4.7 compares the parameters of the hypermetabolic ALS patients with those of the 
normometabolic ALS patients. There was no difference in age, sex ratio, body composition 
data or clinical data between hypermetabolic patients and normometabolic patients. mREE 
was significantly higher in hypermetabolic patients.  
 
Table 4.7 Comparison of demographic, anthropometric and energy expenditure data 
in normometabolic and hypermetabolic ALS patients.  
  Normometabolic ALS 
patients (n=30) 
Hypermetabolic ALS 
patients (n=20) 
p value 
Age 63.02±1.61 (46-80) 59.82±1.77 (46-76) 0.20 
Smoker: non smoker 
ratio 
1:29 2:18 0.56 
Male: Female ratio 19:11  15:5 0.54 
Weight (kg) 73.99±2.77 (48.77-109.41) 80.66±2.92 (58.35-112.81) 0.11 
BMI 25.34±0.68 (18.10-32.15) 26.89±1.10 (20.54-42.49) 0.21 
Fat Mass (kg) 25.45±1.83 (3.10-41.29) 30.91±2.73 (9.27-66.25) 0.09 
Fat Free Mass (kg) 50.62±2.08 (31.30-74.82) 49.74±2.51 (29.52-66.10) 0.79 
mREE (kcal/day) 1414±75.34 (641-2099) 1883±80.32 (1280-2532) <0.01 
pREE (kcal/day) 1381±54.58 (878-2070) 1409±59.08 (878-1791) 0.75 
Metabolic Index 101.35±3.07 (62.48-199.84) 134.14±2.12 (120.40-147.73) <0.01 
Notes: Data presented as mean ± SEM (range). Metabolic Index; mREE/pREE x 100; p value from 
an unpaired Student’s t-test for comparison of quantitative means and from Fishers exact test for 
comparison of ratios. Abbreviations: BMI, body mass index; kcal, kilocalories; mREE, measured 
resting energy expenditure; pREE, predicted resting energy expenditure according to the modified 
Nelson equation as described in Chapter 2 section 2.2.1 and table 2.2. 
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Clinical data is shown in Table 4.8. There was no difference in disease duration, the 
ratio of individuals taking riluzole, the incidence of self-reported weight loss at symptom 
onset or site of disease onset between hypermetabolic and normometabolic patients.  
 
There was no difference in the ALSFRS-R scores between hypermetabolic and 
normometabolic patients. Regarding the clinical examination scores as described by 
Ravits et al (Ravits et al., 2007), the total lower motor neurone (LMN) score was higher in 
the hypermetabolic patients than the normometabolic patients (p=0.04). The mean upper 
motor neurone (UMN) score was lower in the hypermetabolic group but not statistically 
significantly so. 
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Table 4.8 Comparison of clinical data in normometabolic and hypermetabolic ALS 
patients.  
 Normometabolic ALS 
patients (n=30) 
Hypermetabolic ALS 
patients (n=20) 
p value 
Disease duration (months) 27.98±3.57  
(6.83-89.73) 
22.84±4.31  
(2.53-86.43) 
0.37 
Taking riluzole: not taking riluzole 
ratio 
14:16  9:11 >0.99 
Self-reported weight loss:no weight 
loss ratio 
12:18 6:14 0.56 
Limb onset: other site of onset 19:11 16:4  0.35 
Bulbar onset: other site of onset 10:20  4:16  0.35 
Respiratory onset: other site of 
onset 
1:29  0:20 >0.99 
ALSFRS-R Scores    
Total score (of 48) 38.53±0.73 (28-46) 37.33±0.89 (28-45) 0.29 
Bulbar subscore (of 12) 10.37±2.17 (3-12) 10.15±1.87 (7-12) 0.72 
Upper limb subscore (of 8) 6.47±1.89 (2-8) 6.05±1.70 (3-8) 0.43 
Lower limb subscore (of 8) 4.70 ±0.41 (1-8) 4.20±0.39 (1-8) 0.54 
Respiratory subscore (of 12) 11.07±1.32 (6-12) 11.35±0.28 (8-12) 0.54 
Clinical examination scores    
UMN score (of 12) 6.38±0.56 (0-12) 2.88±0.66 (0-10) 0.85 
LMN score (of 12) 2.97±0.42 (0-8) 4.42±0.57 (1-11) 0.04 
Respiratory function tests    
Seated FVC (% of predicted) 91.64±2.84 (59-129) 93.76±3.26 (64-129) 0.30 
Postural change in FVC (%) -11.34±1.62 (-55.38-
8.23) 
-11.96±1.95 (-55.38-
2.57) 
0.45 
SNIP (% of predicted) 60.15±3.42 (16-108) 60.29±4.65 (16-108) 0.12 
Notes: Data presented as mean ± SEM (range). ‘Taking riluzole’ was defined as taking riluzole 
regularly as prescribed for at least 1 month prior to assessment. ALSFRS-R sub-scores as 
described by Pinto et al (Pinto and de Carvalho, 2015). p value from an unpaired Student’s t-test 
for comparison of quantitative means and from Fishers exact test for comparison of ratios. 
Abbreviations: ALSFRS-R, the revised Amyotrophic Lateral Sclerosis functional rating scale; UMN, 
upper motor neurone; LMN, lower motor neurone; UMN and LMN scores determined as described 
by Ravits et al (Ravits et al., 2007); FVC, forced vital capacity; SNIP, maximal sniff nasal 
inspiratory pressure.  
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Clinical correlations of metabolic parameters in ALS patients 
Correlation coefficients from univariate analyses of the REE variables of ALS patients 
versus age at assessment, age at diagnosis of ALS, body-composition variables, 
ALSFRS-R score, UMN and LMN scores, and respiratory function tests are shown in 
Table 4.9.  
 
The mREE significantly correlated with weight and FFM. However, when the REE was 
corrected for FFM (mREE/FFM), the only variable that significantly correlated with 
mREE/FFM was the total LMN score. Similarly, the only variable that significantly 
correlated with the metabolic index was the total LMN score. In contrast, the total UMN 
score poorly correlated with mREE, mREE/FFM and the metabolic index. Linear 
regression plots of the metabolic index versus the ALSFRS-R, FVC and, UMN and LMN 
scores are shown in Figure 4.6. 
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Table 4.9 Correlation coefficients for REE variables against age, composition and 
clinical parameters. Correlation coefficients from univariate analyses. *p<0.05  
  Measured REE Measured REE/FFM Metabolic Index 
Age at assessment -0.42 -0.18 -0.19 
Age at diagnosis of ALS -0.40 -0.19 -0.19 
Weight *0.67 0.30 0.27 
BMI 0.31 0.30 0.19 
FFM *0.66 0.16 0.00 
ALSFRS-R 0.06 -0.25 -0.14 
UMN score 0.15 0.13 0.07 
LMN score 0.22 *0.43 *0.43 
FVC (% predicted) -0.04 -0.13 -0.14 
SNIP (% predicted) -0.02 -0.06 -0.13 
Notes: UMN and LMN scores determined as described by Ravits et al (Ravits et al., 2007). 
Abbreviations: BMI, body mass index; FFM, fat free mass; ALSFRS-R, the revised Amyotrophic 
Lateral Sclerosis functional rating scale; UMN, upper motor neurone; LMN, lower motor neurone. 
FVC, forced vital capacity; SNIP, maximal sniff nasal inspiratory pressure; REE, resting energy 
expenditure; Metabolic Index; measured resting energy expenditure (REE)/predicted REE x 100.  
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Figure 4.6 Correlations between the metabolic index and clinical parameters in ALS 
patients. A significant correlation was observed between the LMN score and metabolic 
index (measured REE/predicted REE x 100). Abbreviations: ALSFRS-R, the revised 
Amyotrophic Lateral Sclerosis functional rating scale; FVC, forced vital capacity (% of 
predicted); SNIP, maximal sniff nasal inspiratory pressure (% of predicted); UMN, upper 
motor neurone; LMN, lower motor neurone. 
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Longitudinal assessment of ALS patients  
 
33 ALS patients underwent a second assessment of ALSFRS-R and body composition 
analysis and after an interval of 3.8 months [115.7 ± 6.12 (82–218) days]. Of these 
patients, 20 were normometabolic and 13 were hypermetabolic at the first assessment. 
Net changes in ALSFRS-R, weight and body composition data between assessments are 
shown in Table 4.10.  
 
 
Table 4.10 Changes in clinical and composition data in 33 ALS patients. Net changes 
in variables between assessments 3.8 months [115.7 ± 6.12 (82–218) days] apart in 33 
ALS patients.  
Change in variables Normometabolic ALS cohort  
(n=20) 
Hypermetabolic ALS cohort  
(n=13) 
p 
value 
ALSFRS-R score -0.10±0.64 (-6-8) -2.46±0.80 (-8-2) 0.02 
Weight (kg) -0.48±0.59 (-6.75-3.04) -0.80±0.10 (-8.17-84.32 0.77 
Fat Mass (kg) -0.21±0.54 (-3.61-3.92) -0.20±0.80 (-5.61-5.92) 0.99 
Fat Free Mass (kg) -0.28±0.33 (-3.13-2.26) -0.72±0.66 (-4.93-4.74) 0.52 
Notes: Normometabolic patients had a metabolic index <120 at the first assessment and 
hypermetabolic patients had a metabolic index ≥ 120 at the first assessment. Metabolic Index; 
measured resting energy expenditure (REE)/predicted REE x 100. p value from an unpaired 
Student’s t-test. Abbreviation: ALSFRS-R, the revised Amyotrophic Lateral Sclerosis functional 
rating scale.  
 
 
The individual changes in normometabolic and hypermetabolic patients are shown in 
Figure 4.7. The patient who was receiving enteral nutrition via a PEG was normometabolic 
and lost 2.35kg of FM and 0.37kg of FFM between assessments.  
 
There was no difference in weight or body composition changes between the 
hypermetabolic patients and the normometabolic patients (Figure 4.7 C-E). However, the 
decline in ALSFRS-R was significantly greater in hypermetabolic patients than in 
normometabolic patients (p=0.02) (Figure 4.7 A and E).  
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Figure 4.7 Comparison of individual changes in clinical and body composition 
measures in 13 hypermetabolic and 20 normometabolic ALS patients. The decline in 
ALSFRS-R score was greater in hypermetabolic patients than normometabolic patients 
(p=0.02). Abbreviations: ALSFRS-R, the revised Amyotrophic Lateral Sclerosis functional 
rating scale; FFM, fat free mass. 
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4.2.5 Summary of findings 
 
A detailed assessment of body composition and energy expenditure was performed in 
50 ALS patients and 50 healthy controls in order to investigate the incidence and clinical 
associations of hypermetabolism. The healthy controls were well matched to the ALS 
patients in age and sex distribution. A subset of ALS patients (n=33) attended a second 
assessment ~4 months later to determine whether hypermetabolism is associated with a 
change in disease progression. 
 
The mean ALSFRS-R score of the ALS patients was 38.04. FFM was significantly 
lower in the ALS patients than in the controls. After accounting for body composition, a 
larger proportion of ALS patients were hypermetabolic compared to the controls (40% in 
ALS patients and 16% in controls).  
 
There was no association between hypermetabolism and the duration, severity, or site 
of onset of disease or, respiratory function. The proportion of patients who were taking 
riluzole and who reported weight loss at symptom onset did not differ between 
hypermetabolic and normometabolic patients. The LMN score determined from clinical 
examination was significantly higher in hypermetabolic patients than in normometabolic 
patients and was correlated with the metabolic index in all ALS patients.  
 
In longitudinal studies there was no difference in change of body weight or composition 
between hypermetabolic and normometabolic patients. A greater decline in mean 
ALSFRS-R score was observed in hypermetabolic patients than in normometabolic 
patients. 
 
This study confirms that a large proportion of ALS patients are hypermetabolic. It is the 
first to show that hypermetabolism is associated with a higher LMN disease burden and a 
greater short-term functional decline than normometabolism. 
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Chapter 5: Discussion, conclusions and future directions 
 
 
In this thesis, studies of the validity of anthropometric predictors of fat mass (FM) and of 
hypermetabolism, using techniques that account for body composition, were carried out in 
ALS patients and matched controls. 
 
5.1 Anthropometric predictors of fat mass in ALS  
 
A version of this section of the thesis was published in IOANNIDES, Z. A., STEYN, F. J., 
HENDERSON, R. D., MCCOMBE, P. A. & NGO, S. T. 2017. Anthropometric measures are 
not accurate predictors of fat mass in ALS. Amyotrophic Lateral Sclerosis and 
Frontotemporal Degeneration, published online 27 Apr 2017. This paper can be found in 
Appendix 2. 
 
The first objective of this thesis was to assess the accuracy of anthropometric 
predictors of FM. This is relevant to routine clinical care of ALS patients as predictors of 
FM could be useful in guiding nutritional management that has been shown to improve 
outcomes in ALS patients (Mazzini et al., 1995, Silva et al., 2010, Dorst et al., 2013, Wills 
et al., 2014). 
 
It was found that body mass index (BMI) and body adiposity index (BAI) were not 
accurate predictors of FM as measured by air displacement plethysmography (ADP) in 
ALS patients. Furthermore, it was shown that longitudinal changes in BMI and BAI did not 
accurately reflect changes in FM. 
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5.1.1 The complex relationship between anthropometric measures and FM 
 
The relationship between BMI, BAI and FM is dependent on sex, age, body shape, 
ethnicity, and the extent and distribution of adiposity (Norgan, 1994).  In non-ALS 
populations, BAI has been shown to over- or underestimate FM in individuals with low or 
high levels of adiposity, respectively (Bergman et al., 2011). Similarly, studies have found 
limitations associated with anthropometric measures as predictors of FM in populations 
with low BMI (Norgan, 1994), obese individuals (Geliebter et al., 2013) and healthy 
sedentary females (Suchanek et al., 2012). 
 
A strength of this study was the inclusion of an age- and sex-matched healthy 
control population. Comparisons between the ALS patients and controls showed that BMI 
and BAI were less accurate predictors of FM in ALS patients than in healthy individuals. 
These findings suggest that factors specific to ALS could reduce the accuracy of 
anthropometric predictors. Altered body composition in ALS patients (Nau et al., 1995, 
Kasarskis et al., 1996, Desport et al., 1999, Desport et al., 2000, Jawaid et al., 2010a) is a 
plausible explanation for these results.  
 
It is known that BMI is inaccurate in individuals with altered fat free mass (FFM), for 
example, in athletes who have increased muscle mass relative to FM (Garrido-Chamorro 
et al., 2009). ALS is characterized by a reduction in muscle mass secondary to neurogenic 
muscle wasting (Kinsley L, 2015 Feb 12). Muscle wasting would result in a lower overall 
body weight, which could reduce BMI. A change in BMI in ALS could therefore be a 
reflection of muscle wasting and not a change in FM.  
 
Hip circumference [the key determinant of BAI and generally accepted as a proxy 
for abdominal adiposity (Bergman et al., 2011)] could also be affected by factors intrinsic 
to the disease process in ALS. For example, redistribution of fat to the abdominal region in 
ALS (Lindauer et al., 2013, Ahmed et al., 2016b) could affect hip circumference, and 
therefore influence BAI. In the ALS patients who underwent longitudinal assessments, 
while the mean BMI and FM measured by ADP did not change, the mean BAI increased 
between assessments (p=0.04). This suggests that hip circumference increased between 
assessments despite there being no change in the mean FM measured by ADP. This 
supports the hypothesis that a change in BAI in ALS patients could occur secondary to a 
change in the distribution but not the overall amount of fat.  
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Ethnicity can also affect body composition estimates (Wagner and Heyward, 2000). 
The original description of BAI was validated in a black African American population 
(Bergman et al., 2011). However, in the present study, the vast majority of the ALS 
patients in this study were of white Caucasian background. This is in keeping with the 
higher incidence of ALS in white Caucasian individuals (compared to black, Asian and 
Hispanic individuals) in large population studies (Cronin et al., 2007, Rechtman et al., 
2015). Therefore, applying BAI to an ALS population that predominantly includes white 
Caucasian individuals, could account for some of the inaccuracy observed between BAI 
and FM in this study.  
 
Altered CNS processes that regulate metabolism could also modify measures of FM 
in ALS. The CNS controls food intake via multiple neuronal populations. Key networks 
exist in the arcuate nucleus of the hypothalamus which involve the anorexigenic (appetite-
suppressing) pro-opiomelanocortin (POMC) neurones and the orexigenic (appetite-
increasing) neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons (Sohn, 
2015). The balance between these hypothalamic networks is crucial in maintaining energy 
homeostasis. Alterations of these complex hypothalamic networks in ALS, either via a 
pathological process or an adaptive response to disease, could affect energy intake and 
therefore modulate energy storage in the form of FM.  
 
Emerging evidence supports the hypothesis that the hypothalamus could play a role 
in mediating fat storage in ALS patients. Hypothalamic atrophy has been observed in ALS 
patients and hypothalamic volume has been found to correlate with BMI, especially in 
individuals with familial ALS (Gorges et al., 2017). Furthermore, observations in ALS 
patients and the SOD1 mouse of a lack of weight gain following treatment with 
pioglitazone, which normally promotes food intake via modulation of hypothalamic 
networks, indicate that the key hypothalamic neuronal networks that control food intake 
could be dysfunctional in ALS (Vercruysse et al., 2016). Additional studies of neuronal 
fibre density in the arcuate nucleus of the hypothalamus in SOD1, TARDP and FUS mice, 
which show a reduction in hypothalamic neurones producing POMC and an increase in 
those producing AgRP (Vercruysse et al., 2016), also suggest an alteration in these 
neuronal types.  
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Therefore, pre-clinical and clinical studies suggest that in ALS there could be 
impairment of hypothalamic neuronal circuitry that regulates food intake and calorie 
balance, which could affect measures of FM. Although this is plausible based on 
knowledge of the normal role of these circuits, further studies elucidating the relationship 
between measures of body composition and the function of these central neuronal 
networks in ALS patients are needed. 
 
5.1.2 Limitations of the study 
 
Limitations of this study include potential error associated with the use of ADP as 
the standard measure of FM. ADP is a reliable and reproducible method for determining 
body composition (Noreen and Lemon, 2006, Anderson, 2007, Lee and Gallagher, 2008) 
and clinical studies suggest that ADP and DEXA measurements of body fat agree within 
1% (Fields et al., 2002). However, it is important to note that this relationship has not been 
studied in ALS. ADP was selected for measurement of FM because many ALS patients 
are unable to lie flat due to respiratory impairment, which could preclude the use of DEXA 
or MRI. Error was minimized by adherence to a strict protocol to minimize extracorporeal 
weight and volume.  
 
Due to the progressive nature of ALS, many of the patients were unable to attend a 
second assessment. The longitudinal assessments were therefore limited to 29 patients. 
Replication of these finding in a larger cohort of patients is needed. 
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5.2 Hypermetabolism in ALS 
 
The second objective was to study hypermetabolism in ALS patients and age- and sex- 
matched controls. This study found that a larger proportion of ALS patients were 
hypermetabolic compared to controls (40% in ALS patients and 16% in controls). This 
confirms previous reports of hypermetabolism in ALS (Kasarskis et al., 1996, Desport et 
al., 2001, Desport et al., 2005, Bouteloup et al., 2009, Funalot et al., 2009, Kasarskis et 
al., 2014). Additionally, this study made the novel observation that hypermetabolism was 
associated with a greater lower motor neurone (LMN) disease burden and a greater short-
term functional decline in ALS patients. 
 
5.2.1 A novel approach to assessing hypermetabolism in ALS 
 
Given the limitations of previous studies of hypermetabolism in ALS (Kasarskis et al., 
1996, Desport et al., 2001, Desport et al., 2005, Bouteloup et al., 2009, Funalot et al., 
2009, Kasarskis et al., 2014), which were discussed in Chapter 1 section 1.2.2, efforts to 
improve upon existing methodologies were made.  
  
This study was novel in accounting for body composition when determining pREE. This 
is a critical consideration because body composition, which has a significant influence on 
REE (Nielsen et al., 2000, Wang et al., 2000, Johnstone et al., 2005, Geisler and Müller, 
2017), is altered in ALS. A decline in FM and FFM (Nau et al., 1995, Kasarskis et al., 
1996, Desport et al., 1999, Desport et al., 2000, Jawaid et al., 2010a) have been reported 
in ALS. Indeed, in this study, the FFM of the ALS patients was significantly lower than that 
of controls. Therefore, when studying hypermetabolism in ALS, allowing for body 
composition was considered to be important. While a number of REE prediction models 
account for FFM (Wang et al., 2000), the Nelson model (Nelson et al., 1992) was used in 
this study as it accounts for FM and FFM, which are both affected in ALS (Nau et al., 1995, 
Kasarskis et al., 1996, Desport et al., 1999, Desport et al., 2000, Jawaid et al., 2010a). 
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Another strength of this study of hypermetabolism is the characteristics of the cohorts. 
Inclusion of a healthy control cohort that was well matched to the ALS cohort for sex and 
age, highlights that the higher incidence of hypermetabolism observed in ALS patients 
compared to healthy controls is likely to be a consequence of changes specific to ALS.  
 
Regarding the ALS cohort, the mean ALSFRS-R score was 38.04. Prior studies of 
hypermetabolism in ALS predominantly assessed patients with advanced disease (the 
mean ALSFRS-R scores in prior studies were between 27.6 and 35.7 see table 1.1, 
section 1.2.2) (Kasarskis et al., 1996, Desport et al., 2001, Desport et al., 2005, Bouteloup 
et al., 2009, Funalot et al., 2009, Kasarskis et al., 2014). Given that a lower ALSFRS-R 
score indicates worse disability, the patients assessed in this study had less disability and 
were at an earlier stage in the disease process than prior studies. The current results can 
therefore give insights into the incidence and correlates of hypermetabolism earlier in 
disease than previously studied. 
 
A stricter definition of hypermetabolism (mREE ≥ 120% of pREE) was applied in this 
study compared to previous studies in ALS, which used ≥ 110% as the threshold for 
hypermetabolism. This stricter definition was applied to be in accord with studies of 
patients with insulin resistance, diabetes and liver cirrhosis (Muller et al., 1999, Perseghin 
et al., 2002), in whom hypermetabolism is common (Muller et al., 1993). The use of a more 
stringent threshold for hypermetabolism is likely to explain the lower incidence of 
hypermetabolism in this study compared to some previous studies (Desport et al., 2001, 
Desport et al., 2005, Funalot et al., 2009, Bouteloup et al., 2009) as outlined in table 1.1.  
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5.2.2 Clinical correlates of hypermetabolism in ALS 
 
In order to gain insights into the pathogenesis of hypermetabolism, we aimed to identify 
clinical factors that correlate with increasing energy expenditure. This is necessary 
because ALS is recognized to be a highly heterogeneous disorder (Turner et al., 2010). In 
particular, patients differ in the site of disease onset and in their motor features, leading to 
a number of different classification systems or ‘disease phenotypes’ (Talman et al., 2009). 
Patients also vary in the presence or absence of cognitive impairment (Xu et al., 2017) 
and in the presence or absence of other non-motor issues (McCombe et al., 2017). 
 
In this study, the effect of site of disease onset and degree of upper motor neurone 
(UMN) and lower motor neurone (LMN) involvement on the presence of hypermetabolism 
was investigated. The severity of UMN and LMN involvement were recorded using a 
clinical scoring system that grades UMN and LMN signs in each body region from a 
physical examination (Ravits et al., 2007). The original authors of this grading system used 
it to demonstrate the focality of upper and lower motor neurone degeneration in ALS 
(Ravits et al., 2007). It has subsequently been used to show that LMN burden is 
associated with survival in ALS (Devine et al., 2016). 
 
The site of disease onset did not differ between hypermetabolic and normometabolic 
ALS patients. However, it was found that hypermetabolism was associated with a 
significantly higher LMN score. Furthermore, the REE corrected for FFM and the metabolic 
index, significantly correlated with the total LMN score. Whilst these correlations do not 
confirm causation, they raise the possibilities that hypermetabolism could increase the 
severity of LMN clinical signs, or conversely, that a greater LMN burden could be a risk 
factor for hypermetabolism.  
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5.2.3 Possible sites for the origin of hypermetabolism in ALS  
 
At present the cause of hypermetabolism in ALS remains unknown. An important 
unanswered question is which tissues have an increased metabolic rate? The clinical 
correlations revealed in this study, although not confirming causation, allow plausible sites 
for the origin on hypermetabolism in ALS to be hypothesized. 
 
A greater LMN score arises when there are a greater number of dysfunctional motor 
units. The association between hypermetabolism and LMN disease burden suggests that 
motor unit abnormalities could be linked to hypermetabolism in ALS. Abnormal motor unit 
physiology is well described in pre-clinical models of ALS (Gurney et al., 1994, Frey et al., 
2000, Schaefer et al., 2005, Kryściak et al., 2014) and ALS patients (Henderson et al., 
2009, de Carvalho et al., 2012, Piotrkiewicz and Hausmanowa-Petrusewicz, 2013, de 
Carvalho et al., 2014).   
 
  A motor unit is made up of a motor neurone, its neuromuscular junctions and 
skeletal muscle fibers that are innervated by its axonal terminals (Purves D, 2001) (figure 
5.1). It is possible that abnormalities at each of these sites could contribute to 
hypermetabolism in ALS. 
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Figure 5.1 The motor unit. A single motor unit comprising the lower motor neurone from 
the spinal cord to the neuromuscular junction and the innervated skeletal muscle fibres. 
(from Dictionary of Sport and Exercise Science and Medicine by Churchill Livingstone, 
2008 Elsevier Limited; http://medical-dictionary.thefreedictionary.com/motor+unit) 
 
 
As skeletal muscle accounts for up to 30% of total energy expenditure at rest (Rolfe 
and Brown, 1997) and is a major determinant of resting energy expenditure (Zurlo et al., 
1990), it is a plausible site for the origin of hypermetabolism. Skeletal muscle is heavily 
dependent on glucose as its primary energy source under normal physiological conditions, 
only switching to lipid as an alternate energy source when the available glucose is unable 
to sustain energy requirements (Randle, 1998). Although lipid oxidation provides more 
ATP than glucose, it requires more oxygen per mole of ATP synthesized, thus lipid 
oxidation is accompanied by a higher rate of oxygen consumption (Randle, 1998, Leverve 
et al., 2007).  
 
In chronic denervation, studies of rats (Pak et al., 2016) and patients (Karpati et al., 
1979) show increased uptake of glucose and lipids from arterial blood, suggesting that 
denervation results in increased energy use. Rat studies suggest that denervation is 
associated with a reduction in the expression of glucose transporters (Henriksen et al., 
1991, Coderre et al., 1992) and an increased turnover of proteolipid receptors (Lunt et al., 
1971) which could affect the transport of energy substrate into skeletal muscle. In line with 
this, altered energy substrate preference in skeletal muscle, characterized by an increase 
in lipid oxidation and reduction in glucose utilization, has been observed in hypermetabolic 
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SOD1 mice (Palamiuc et al., 2015). As lipid oxidation consumes more oxygen than 
glucose oxidation, if this preference towards lipid metabolism in muscle occurs in a 
widespread fashion, it could translate into increased overall energy consumption and 
contribute to hypermetabolism.   
 
Mitochondria, the main site of oxidative phosphorylation and production of ATP, 
play a pivotal role in bioenergetics and survival of the cell. As skeletal muscle and 
neuronal cells have a high-energy requirement, mitochondria are critical to sustaining their 
function and maintaining energy homeostasis [reviewed in (Xavier et al., 2015)]. The 
mitochondrial respiratory chain provides the energy necessary for mitochondrial ATP 
synthesis and calcium handling. Morphological alterations and functional impairments, 
including defects in the activities of mitochondrial respiratory chain complexes, have been 
detected in skeletal muscle and neuronal tissue of ALS patients (Afifi et al., 1966, Hervias 
et al., 2006, Martin, 2011, Pansarasa et al., 2014). It is possible that inefficient energy 
production via defects in the mitochondrial respiratory chain could increase muscle and 
neuronal energy requirements and therefore contribute to hypermetabolism. 
 
The metabolic and physiological consequences of denervation have led to the long-
standing theory that denervated muscle acts like fatigued muscle (Langley, 1916). This is 
possibly due to fasciculations and trophic processes such as re-innervation (Bass, 1962). 
With this in mind, the processes of neuronal repair that follow denervation in ALS could 
significantly affect energy requirements.   
 
Neuromuscular junction disruption also occurs in ALS (Dupuis and Loeffler, 2009, 
Campanari et al., 2016). It has been proposed that hypermetabolism of skeletal muscle 
origin in SOD1 mice could lead to destruction of the neuromuscular junction and further 
axonal degeneration (Dupuis and Loeffler, 2009). Although the mechanism of this 
proposed chain of events in ALS is not known, this theory suggests that a complex 
relationship between hypermetabolism and neuronal loss could exist. 
 
Denervation results in the production of a range of factors that are trophic for motor 
axons (Henderson et al., 1983), including insulin-like growth factors (Day et al., 2001, 
Shavlakadze et al., 2005) and myogenic regulatory factors (Walters et al., 2000). 
Denervated muscle cells undergo a change in the expression of genes encoding cell cycle 
regulators and extracellular matrix components (Batt et al., 2006). Denervated muscle 
 116 
cells also secrete immune molecules (interleukins) and metabolic factors (Pedersen, 
2011). These responses lead to the sprouting of new axons and re-innervation of muscle 
fibres by axons from other motor units.  
 
Successful collateral re-innervation during the early stages of ALS is demonstrated by 
the neurophysiological finding of large motor units in ALS patients (Duleep and Shefner, 
2013). However, as disease progresses there is a failure in adequate re-innervation, which 
is followed by muscle atrophy (Bonaldo and Sandri, 2013). Physiological abnormalities 
including abnormal LMN firing (de Carvalho et al., 2014, Howells et al., 2016) and 
fasciculations (Piotrkiewicz and Hausmanowa-Petrusewicz, 2013) accompany these 
changes. In the event of widespread denervation, as seen in ALS, the energy costs 
associated with these neuronal changes could be significant and potentially contribute to 
increased systemic energy requirements.  
 
Although it is hypothesized that hypermetabolism in ALS originates from abnormal 
motor units, it is possible that a systemic derangement in energy metabolism also occurs 
as a related phenomenon. Indeed, altered glucose metabolism associated with 
denervation, is not confined to the affected muscles. Abnormal glucose metabolism has 
been observed in tissues distant from the site of denervation in animal studies (Nunes and 
de Mello, 2005). Studies of denervated rats show a generalized reduction in glucose 
uptake, glycogen synthesis, insulin sensitivity (Nunes and de Mello, 2005) and an 
enhanced effect of epinephrine on glycogen metabolism (Moruzzi and Bergamini, 1983). 
Given that these hormones have widespread effects throughout the body, these 
observations support the notion that denervation could lead to extensive changes in 
energy metabolism that extend beyond muscle physiology.  
 
Much of the evidence supporting metabolic change in motor units following denervation 
arises from studies of denervation of isolated nerves in pre-clinical models. Extrapolating 
from these results, it is feasible that the mass synchronous denervation that occurs in ALS 
could have systemic metabolic consequences and could underlie the metabolic changes 
observed in patients.  
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Respiratory dysfunction has also been hypothesized to contribute to hypermetabolism, 
as discussed in section 1.2.2. This study found no correlation between the metabolic 
index and respiratory parameters. This is in line with previous studies showing a lack of 
association between forced vital capacity (FVC) and hypermetabolism in ALS patients 
(Desport et al., 2005, Bouteloup et al., 2009). In addition to the FVC, in this study a more 
sensitive measure of mild to moderate respiratory muscle weakness, the maximal sniff 
nasal inspiratory pressure (SNIP) (Lyall et al., 2001) was also recorded, however the lack 
of correlation between respiratory function and metabolic parameters remained. These 
results imply that factors other than respiratory dysfunction play a role in hypermetabolism.  
 
Cortical hyperexcitablity (Vucic and Kiernan, 2006, Vucic et al., 2008) is another 
potential contributor to hypermetabolism in ALS (discussed in section 1.2.2). However, 
our study showed that use of riluzole, an inhibitor of glutaminergic transmission that has 
been show to modulate cortical hyperexcitability in ALS (Geevasinga et al., 2016), was not 
associated with a reduction in the incidence of hypermetabolism. Although riluzole has 
only a modest effect on hyperexcitability, this observation suggests that although 
hyperexcitability could contribute to hypermetabolism, other factors appear to be 
important. 
 
5.2.4 Hypermetabolism as a modifier of functional decline 
 
Longitudinal assessment of a subset of ALS patients evaluated how hypermetabolism 
influences changes in functional disability, weight and body composition over time. 
Hypermetabolic patients experienced a greater decline in function, as assessed by the 
ALSFRS-R, when compared to normometabolic patients. This is in line with the findings of 
Desport et al who observed that REE correlated with a worsening of ALSFRS-R scores in 
ALS patients (Desport et al., 2005). However, an earlier study by the same author did not 
observe a correlation between spasticity scores or level of fasciculations in ALS patients 
and REE (Desport et al., 2001). This reflects the limitations of clinical markers, which do 
not necessarily follow the underlying pathophysiological changes of ALS. 
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The finding of a greater functional decline in hypermetabolic patients suggests that 
hypermetabolism could be linked to a poorer survival. Notably, it has been shown that a 
transgenic mouse model engineered to exhibit muscle-specific hypermetabolism, 
displayed the hallmarks of ALS including neuro-muscular junction damage and motor 
neurone degeneration (Dupuis et al., 2009). This indicates that hypermetabolism could 
exacerbate neuronal loss.  
 
Although a causal relationship between hypermetabolism and survival has not been 
confirmed in ALS, hypermetabolism is known to predict a shorter survival in other 
disorders including cancer (Vazeille et al., 2017), sepsis (Wu et al., 2015a) and burns 
(Herndon  et al., 2001). Evidence from dietary studies in ALS suggests that 
hypermetabolism and survival could be linked. Increased caloric intake is associated with 
an improved survival in ALS and a possible mechanism of benefit is that increased energy 
intake compensates for the increased energy demands associated with hypermetabolism. 
In 2004 it was shown that a high calorie diet extended mean survival by 20% in SOD1 
mice (Dupuis et al., 2004). More recently, studies in ALS patients have shown that high 
caloric food supplements stabilize body weight (Dorst et al., 2013), increase BMI (Silva et 
al., 2010) and reduce mortality (Mazzini et al., 1995, Wills et al., 2014, Dorst et al., 2015).   
 
The occurrence of hypermetabolism was not documented in these studies that showed 
a benefit of increased caloric intake. However, as between 25-70% of sporadic ALS 
patients are hypermetabolic (Kasarskis et al., 1996, Desport et al., 2001, Desport et al., 
2005, Bouteloup et al., 2009, Funalot et al., 2009, Kasarskis et al., 2014), these findings 
could suggest that compensating for the increased energy demands of hypermetabolism, 
could improve survival.  
 
Whether hypermetabolism is associated with a worse outcome remains to be 
confirmed as there are conflicting findings in the previous reports. Although Karsarkis et al 
found that mREE/pREE increased as death approached in 16 ALS patients, Bouteloup et 
al, found that the survival of hypermetabolic ALS patients was not significantly different to 
that of normometabolic patients (Bouteloup et al., 2009). Desport et al found that mREE 
remained stable as 62 ALS subjects approached death (Desport et al., 2001) and that 
mREE, corrected for FFM, decreased relative to proximity to death in 168 ALS patients 
(Desport et al., 2005).  
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Although it would be expected that hypermetabolism would lead to negative energy 
balance and weight loss, there was no difference between hypermetabolic patients and 
normometabolic patients in the occurrence of weight loss at symptom onset or weight loss 
over the ~4 month follow-up period. The absence of excessive weight loss in 
hypermetabolic individuals suggests that compensation could occur, either as a result of 
increased energy intake or a reduction in other sources of energy expenditure, namely 
activity dependent energy needs and the thermic effect of food. 
 
5.2.5 The hypothesized vicious cycle of hypermetabolism 
 
As discussed above, the finding that LMN dysfunction is associated with hypermetabolism, 
raises the possibility that increased energy demands of diseased motor units drive 
hypermetabolism. In addition to this, the observation that hypermetabolism is associated 
with a greater functional decline in ALS patients, leads to the hypothesis that 
hypermetabolism could increase motor neurone vulnerability and accelerate disease 
progression in ALS. These two hypotheses and a prior report that greater LMN dysfunction 
is associated with a poorer survival in ALS patients (Devine et al., 2016), can be linked to 
hypothesize that hypermetabolism of motor unit origin leads to metabolic changes that 
could exacerbate disease progression. This is outlined in figure 5.2.  
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Figure 5.2 The hypothesized link between hypermetabolism, lower motor neurone 
dysfunction, motor unit abnormality and survival in ALS. The results of this study 
suggest that hypermetabolism is associated with LMN dysfunction (1) and disease 
progression (3). From these results it is hypothesized that hypermetabolism arises from 
diseased motor units (2) and that hypermetabolism leads to a vicious cycle of accelerated 
disease progression (4), further LMN degeneration and exacerbation of hypermetabolism. 
In addition to this, Devine et al (Devine et al., 2016) showed that LMN burden is 
associated with a worse survival (5). Therefore, it is also hypothesized that 
hypermetabolism is linked to poor survival (6). Blue arrows indicate known associations. 
Red arrows and question marks indicate hypothesized associations or relationships. 
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5.2.6 Limitations of the study 
 
Methodological limitations of the use of the ADP as the measure for body composition 
used to predict REE are discussed above in section 5.1.2. 
 
It should be noted that although LMN and UMN scores were assessed in an 
unbiased way, this clinical approach is not as rigorous as other techniques, for example 
neurophysiological assessments. The longitudinal portion of this study is limited by the use 
of ALSFRS-R as the sole marker of disease progression, the relatively short follow-up 
period and the lack of long-term survival data. Furthermore, due to the progressive nature 
of ALS, the longitudinal assessments were limited to 33 individuals.  
 
 
5.3 Potential future directions 
 
Regarding the studies of anthropometric measurements, given that neurogenic muscle 
wasting could contribute to the inaccuracy of predictions of FM in ALS patients, 
incorporation of anthropometric measurements of muscle wasting could allow the loss of 
muscle mass to be taken into account. For example, arm muscle area calculated from 
triceps skinfold thickness and mid-arm circumference, allows total body muscle mass to be 
predicted (Heymsfield et al., 1982). Studies assessing the combined use of BMI, BAI and 
anthropometric predictors of muscle mass could be useful in developing a practical 
approach to predicting FM specifically in ALS patients. 
 
Redistribution of FM could also contribute to the inaccuracy of anthropometric 
predictors of FM in ALS patients. MRI studies of regional adiposity could therefore be 
useful in characterizing changes in the distribution of FM. Indeed, studies assessing 
whether MRI changes in body composition, including muscle wasting or redistribution of 
FM, correlate with anthropometric predictors in ALS patients, could be useful in the 
development ALS-specific predictors of adiposity. MRI could also provide quantification of 
FFM, which could allow for more accurate predictions of REE in future studies of 
hypermetabolism.  
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Future studies of hypermetabolism in ALS could benefit from a combination of clinical, 
functional and electrophysiological parameters for monitoring disease progression and, 
UMN and LMN disease burden. For example, motor unit number estimations (MUNE) 
(Gooch et al., 2014, Henderson and McCombe, 2017) could be a useful quantitative 
method of following motor unit physiology. Likewise, UMN disease burden could be better 
assessed by transcranial magnetic stimulation (TMS) techniques, which reflect 
corticomotoneuronal function (Vucic and Kiernan, 2013). Furthermore, longitudinal 
assessment of changes in LMN and UMN disease burden in relation to the onset of 
hypermetabolism, could provide insights into whether the progression of LMN and/or UMN 
involvement affect the development of hypermetabolism. 
 
Prospective longitudinal assessments of changes in metabolic status and survival in 
ALS patients are necessary to determine whether hypermetabolism is associated with a 
worse survival. The observed associations between hypermetabolism and LMN 
dysfunction and disease progression, also require confirmation in a larger cohort.  
 
Given that hypermetabolism was not associated with weight loss, investigation of other 
factors that could be altered in compensation for the increased energy expenditure of 
hypermetabolism is warranted. This would include assessments of dietary intake, appetite, 
activity dependent energy needs and the thermic effect of food. 
 
It is important to note that the observations presented in the thesis are associations 
and although they enable the development of hypothetical mechanisms, they do not 
confirm causation. Physiological studies of energy substrate use and energy requirement 
in muscle and neuronal tissue from ALS patients relative to whole body energy 
expenditure are required in order to clarify whether altered motor unit energy expenditure 
is associated with hypermetabolism in ALS. If it is found that motor unit metabolism is 
altered in hypermetabolic patients, the specifically affected pathways could be modified 
and the effect on hypermetabolism and disease progression assessed. This could provide 
insights into the cause and clinical consequence of hypermetabolism.  
 
An important unanswered question is when does hypermetabolism occur in the course 
of ALS? Although this study was unique in assessing patients relatively early in their 
disease course, it is possible that pathological changes occur prior to the onset of 
symptoms in individuals at risk of developing ALS (Vucic et al., 2008). Therefore, 
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longitudinal assessment of pre-symptomatic individuals who harbour genetic mutations for 
the development of ALS could reveal insights into the development of hypermetabolism in 
relation to the emergence of clinically apparent disease. Given that familial ALS appears to 
be associated with a high incidence of hypermetabolism (Funalot et al., 2009), the 
assessment of genetically at risk individuals could be a useful approach. 
 
It is also unknown how the extra-motor features of ALS, such as cognitive impairment, 
affect metabolism. Altered metabolism (Ahmed et al., 2014a) and changes in energy 
expenditure (Ahmed et al., 2016c) have been reported in patients with frontotemporal 
dementia (FTD). Cognitive impairment similar to that seen in FTD occurs in some ALS 
patients (Xu et al., 2017), and ALS and FTD appear to exist at opposite ends of a common 
disease spectrum (Ahmed et al., 2016a, De Silva et al., 2016). However, compared to 
patients with ALS, patients with FTD display a distinct metabolic profile, characterized by a 
higher BMI (Ahmed et al., 2014b) and altered eating patterns (Ahmed et al., 2016b). 
These findings suggest that cognitive impairment could play a role in centrally modifying 
behaviours that could affect metabolism. The one ALS patient with FTD in this study was 
found to have a low metabolic index, however, larger studies are required of the effects on 
metabolism of cognitive impairment in ALS.  
 
 
5.4 Overall Conclusions 
 
ALS is a fatal disease with no cure. Identification of factors that could modify disease 
progression is therefore vital. Metabolic dysfunction is increasingly recognized to occur in 
some ALS patients and could modify the course of disease. Of clinical significance, 
alterations in fat mass (FM) (Desport et al., 1999, Paganoni et al., 2011) and 
hypermetabolism (Kasarskis et al., 1996) could be associated with a worse disease 
outcome. Therefore, improved methods to assess these factors and a greater 
understanding of their clinical associations are important.   
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In this thesis, the accuracy of anthropometric predictors of FM and the incidence 
and clinical correlations of hypermetabolism were examined in ALS patients. 
 
Using ADP as the standard, it was found that BMI and BAI are not accurate 
predictors of FM and that they provide a poor indicator of change in FM over time in ALS 
patients. It is likely that changes in BMI and BAI in ALS patients occur independent to 
changes in FM alone. Changes in BMI and BAI could depend on muscle atrophy and re-
distribution of fat in individual ALS patients.  
 
Given that measures of adiposity guide nutritional therapies in ALS, inaccurate 
estimation of FM or misleading estimates of changes in FM could have adverse clinical 
consequences. When possible, more accurate measures of body composition should be 
sought in ALS patients. 
 
 It was also found that when body composition is accounted for, the incidence of 
hypermetabolism is greater in ALS patients than in healthy matched controls. This study is 
the first to demonstrate an association between hypermetabolism and LMN disease 
burden and a greater functional decline in ALS patients. In light of these results it is 
hypothesized that hypermetabolism arises from abnormal motor units. Furthermore, it is 
hypothesized that hypermetabolism could drive progression of ALS and lead to a vicious 
cycle of denervation, hypermetabolism and further disease progression (figure 5.2).  
 
Overall, the results of this thesis suggest that BMI and BAI are inadequate markers 
of nutritional status in ALS and that hypermetabolism is an important metabolic 
consideration in ALS patients. ALS-specific predictors of FM are required to guide 
nutritional therapies and further clinical and physiological studies are needed to 
understand the cause and prognostic implications of changes in body composition and 
hypermetabolism.  
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